


Case 23622

BENZOYL-PIPERIDINE DERIVATIVES AS 5HT₂/D₃ MODULATORS

In particular, the present invention relates to compounds of the general formula



wherein:

- A is aryl or 5 to 6 membered heteroaryl optionally substituted by one to five
 5 substituents selected from the group consisting of cyano, halo, C₁₋₆-alkyl, C₁₋₆-haloalkyl, C₁₋₆-alkylsulfonyl, or C₁₋₆-alkoxy;
- n is 1, 2, 3 or 4;
- p is 1, 2, 3 or 4;
- q is 0 or 1;
- 10 r is 0, 1, 2 or 3;
- R¹ is C₂₋₆-alkenyl or C₂₋₆-alkynyl substituted by aryl,
 or is C₁₋₆-alkyl optionally substituted by one to five substituents selected from the
 group consisting of:
- halo,
- 15 hydroxy,
- C₁₋₆-alkyl,
- C₁₋₆-haloalkyl,
- CO(O)-C₁₋₆-alkyl,
- C₃₋₁₀-cycloalkyl,
- 20 C₁₋₆-alkoxy optionally substituted by one, two or three halo or substituted by aryl,
 aryl optionally substituted by halo or C₁₋₆-alkoxy,
 5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl, and
 phenoxy,

or is C₁₋₆-alkoxy,
 or is C₃₋₁₀-cycloalkyl optionally substituted by one or more R^a,
 or is 4 to 10 membered heterocycloalkyl optionally substituted by one or more R^a,
 or is aryl optionally substituted by one or more R^a,
 5 or is 5 to 10 membered heteroaryl optionally substituted by one or more R^a,
 or is -NR^bR^c, wherein R^b is H or C₁₋₆-alkyl and wherein R^c is H, C₁₋₆-alkyl or aryl
 optionally substituted by one or more R^a,

wherein R^a is selected from:

halo,
 10 cyano,
 oxo,
 hydroxy,
 halobenzenesulfonyl,
 C₁₋₆-alkyl optionally substituted by one, two or three substituents
 15 selected from the group consisting of:
 5 to 10 membered heterocycloalkyl, and
 aryl which is optionally substituted by halo or by C₁₋₆-alkoxy,
 C₁₋₆-haloalkyl,
 C₁₋₆-haloalkoxy,
 20 C₁₋₆-alkoxy optionally substituted by aryl or 5 to 10 membered
 heteroaryl which is optionally substituted by C₁₋₆-alkyl,
 aryloxy,
 -NH(CO)-C₁₋₆-alkyl,
 -O(CO)-C₁₋₆-alkyl,
 25 C₁₋₆-alkylsulfonyl,
 aryl,
 4 to 10 membered heterocycloalkyl optionally substituted by
 hydroxy, C₁₋₆-alkyl or oxo,
 5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl or
 30 oxo, and
 di(C₁₋₆)alkylamino;

R² is H, OH, C₁₋₆-alkyl or halo;

as well as pharmaceutically acceptable salts thereof.

It has been surprisingly found that the compounds of formula (I) according to the
 35 invention are dual modulators of the serotonin 5-HT_{2a} and dopamine D₃ receptors.

The compounds of the invention have high affinity for the dopamine D₃ and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT_{2A} receptors and are believed to be effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment. Psychotic disorders encompass a variety of diseases, which include schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and other psychoses involving paranoia and delusions.

In particular schizophrenia is characterized by complex symptomatology including positive symptoms, (i.e. delusions and hallucinations), and negative symptoms, (i.e. anhedonia, restricted fluency and productivity of thought and speech). In addition it is now well recognized that cognitive impairment is the third major diagnostic category of schizophrenia, characterized by loss in working memory as well as other deficits. Other symptoms include aggressiveness, depression and anxiety (Stahl, S. M. (2000) *Essential Psychopharmacology. Neuroscientific Basis and Practical Applications*. Cambridge University Press, second edition, Cambridge, UK). The different categories and the clinical features of the disorder are defined in diagnostic schemes such as DSM-IV (Diagnostic and statistical manual of mental disorders, 4th edition) or ICD-10 (International classification of diseases, 10th edition). Currently used medications to treat schizophrenia, bipolar mania and other psychoses, include antipsychotics both typical (D₂/D₃ preferring) or the more recent atypicals, which exhibit polypharmacology interacting at multiple receptors (eg., D₁, D₂, D₃, D₄, 5-HT_{1A}, 5-HT_{2A}, 5-HT_{2C}, H₁, M₁, M₂, M₄, etc; Roth, B. L. et al. (2004) *Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia*. *Nat. Rev. Drug Discov.* 3, 353-359). These antipsychotics, although relatively successful (some patients exhibit treatment resistance) at treating the positive symptoms of schizophrenia, are less effective at treating negative symptoms, cognitive deficits, and associated depression and anxiety, all of which lead to reduced patient quality of life and socioeconomic problems (Lieberman, J. A. et al. *Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators*. (2005) *Effectiveness of antipsychotic drugs in patients with chronic schizophrenia*. *N. Engl. J. Med.* 353, 1209-1223). Furthermore, patient compliance is compromised by prevalent side effects such as weight gain, extrapyramidal symptoms (EPS), and cardiovascular effects (Lieberman, J. A. et al. *Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators*. (2005) *Effectiveness of antipsychotic drugs in patients with chronic schizophrenia*. *N. Engl. J. Med.* 353, 1209-1223). In the current invention, compounds with high affinity and greater

selectivity for D₃ and 5-HT_{2A} receptors are described and are proposed to treat psychoses and other diseases, with fewer associated side affects.

Dopamine, a major catecholamine neurotransmitter, is involved in the regulation of a variety of functions which include emotion, cognition, motor functions, and positive reinforcement, (Purves, D. et al. (2004) Neuroscience. Sinauer, third edition, Sunderland, Massachusetts). The biological activities of dopamine are mediated through G protein-coupled receptors (GPCRs) and in human, five different dopamine receptors D₁-D₅ have been identified, where the D₂-like receptors (D₂, D₃ and D₄) couple to the G-protein G_{αi} (Missale, C. et al. (1998) Dopamine receptors: from structure to function. *Physiol. Rev.* 78, 189-225). The D₃ dopamine receptor is most highly expressed in the nucleus accumbens (Gurevich, E. V., Joyce, J. N. (1999) Distribution of dopamine D₃ receptor expressing neurons in the human forebrain: comparison with D₂ receptor expressing neurons. *Neuropsychopharmacology* 20, 60-80), and is proposed to modulate the mesolimbic pathway consisting of neuronal projections from the ventral tegmental area, hippocampus and amygdala to the nucleus accumbens, which projects to the prefrontal and cingulate cortices as well as various thalamic nuclei. The limbic circuit is thought to be important for emotional behavior and thus D₃ receptor antagonists are proposed to modulate psychotic symptoms such as hallucinations, delusions and thought disorder (Joyce, J. N. and Millan, M. J., (2005) Dopamine D₃ receptor antagonists as therapeutic agents. *Drug Discovery Today*, 1 Jul, Vol. 10, No. 13, 917-25), while these antagonists spare the D₂ modulated striatal extrapyramidal system (associated with EPS induction). In addition, it has been reported that drug naive schizophrenic patients show altered levels of D₃ receptor expression (Gurevich, E. V. et al. (1997) Mesolimbic dopamine D₃ receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. *Arch. Gen. Psychiatry* 54, 225-232) and dopamine release (Laruelle, M. (2000) Imaging dopamine dysregulation in schizophrenia: implication for treatment. Presented at Workshop Schizophr.: Pathol. Bases and Mech. Antipsychotic Action, Chicago), indicating that a disturbed homeostasis of dopamine plays an important role in the etiology of schizophrenic symptoms.


The neurotransmitter serotonin is implicated in several psychiatric conditions including schizophrenia (Kandel, E. R. et al. (eds.; 2000) Principles of Neural Science, 3rd edition Appleton & Lange, Norwalk, CT). The involvement of serotonin in psychotic disorders is suggested by multiple studies which include treatment in humans with the psychotropic drug Lysergic acid (LSD; a serotonin agonist) which can induce schizophrenia-like symptoms such as hallucinations (Leikin, J. B. et al. (1989) Clinical

features and management of intoxication due to hallucinogenic drugs. *Med. Toxicol. Adverse Drug Exp.* 4, 324-350). Furthermore, altered brain distribution of serotonin receptors as well as an altered serotonergic tone, have been detected in schizophrenic patients (Harrison, P. J. (1999) Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT_{2A} receptors. *Br. J. Psychiatry Suppl.* 38, 12-22). In mammals serotonin exerts its biological activities through a family of 14 5-HT GPCRs (Barnes, N. M., Sharp, T. (1999) A review of central 5-HT receptors and their function. *Neuropharmacology* 38, 1083-1152). The 5-HT_{2A} receptor is most prominently expressed in the prefrontal cortex and at lower levels in the basal ganglia and the hippocampus in human brain (Pompeiano, M. et al. (1994) Distribution of the serotonin 5-HT₂ receptor family mRNAs: comparison between 5-HT_{2A} and 5-HT_{2C} receptors. *Brain Res. Mol. Brain Res.* 23, 163-178; Pazos, A., Probst, A., Palacios, J. M. (1987) Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors. *Neuroscience* 21, 123-139), and is coupled predominantly to the G-protein G_{αq} (Roth, B. L. et al. (1998) 5-Hydroxytryptamine-2-family receptors (5-hydroxytryptamine_{2A}, 5-hydroxytryptamine_{2B}, 5-hydroxytryptamine_{2C}): where structure meets function. *Pharmacol. Ther.* 79, 231-257). Genetic linkage studies of a 5-HT_{2A} polymorphism to schizophrenia (Spurlock, G. et al. (1998) A family based association study of T102C polymorphism in 5HT_{2A} and schizophrenia plus identification of new polymorphisms in the promoter. *Mol. Psychiatry* 3, 42-49), as well as responsiveness to antipsychotic drugs (Arranz, M. J. et al. (2000) Pharmacogenetic prediction of clozapine response. *Lancet* 355, 1615-1616), further suggests a role for the 5-HT_{2A} receptor both in the treatment and pathology of psychosis. In addition, dopaminergic neurotransmission appears to be under the afferent regulation of the 5-HT_{2A} receptor (Porras, G. et al. 5-HT_{2A} and 5-HT_{2C/2B} receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. *Neuropsychopharmacology* 26, 311-324 - 2002). Overall 5-HT_{2A} receptor antagonists are proposed to be suitable for the treatment of disorders associated with dysfunctional dopaminergic systems. Moreover, 5-HT_{2A} receptor antagonism has been recognized as beneficial for the treatment of psychosis (reviewed in de Angelis, L. (2002) 5-HT_{2A} antagonists in psychiatric disorders. *Curr. Opin. Investig. Drugs* 3, 106-112) and indeed is one of the defining features of so-called atypical antipsychotic drugs which are characterized by a relatively high affinity for the 5-HT_{2A} - relative to the D₂ receptor (Meltzer, H. Y. et al. (1989) Classification of typical and atypical antipsychotic drugs on the

basis of dopamine D-1, D-2 and serotonin₂ pK_i values. J. Pharmacol. Exp. Ther. 251, 238-246).

As mentioned hereinabove, the compounds of the invention have high affinity for the dopamine D₃ and serotonin 5-HT_{2A} receptors and are expected to be effective in the treatment of psychotic disorders which include schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and other psychoses involving paranoia and delusions (Reavill-C, et al. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D₃ receptor antagonist, SB-277011-A. JPET 294:1154-1165; Harrison, P. J. (1999) Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D₁, D₃, D₄) and 5-HT_{2A} receptors. Br. J. Psychiatry Suppl. 38, 12-22; de Angelis, L. (2002) 5-HT_{2A} antagonists in psychiatric disorders. Curr. Opin. Investig. Drugs 3, 106-112; Joyce, J. N. and Millan, M. J., (2005) Dopamine D₃ receptor antagonists as therapeutic agents. Drug Discovery Today, 1 Jul, Vol. 10, No. 13, P. 917-25); drug dependency and abuse and withdrawal (Vorel, S. R. et al. (2002) Dopamine D₃ receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci., 22, 9595-9603; Campos, A. C. et al. (2003) The dopamine D₃ receptor antagonist SB277011A antagonizes nicotine-enhanced brain-stimulation reward in rat. Soc. Neurosci. Abstr., 322.8; Ashby, et al. (2003) Acute administration of the selective D₃ receptor antagonist SB-277011-A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse, 48, 154-156); anxiety, and depression (Reavill-C et al. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D₃ receptor antagonist, SB-277011-A. JPET 294:1154-1165; Drescher, K. et al. (2002) In vivo effects of the selective dopamine D₃ receptor antagonist A-437203. Am. Soc. Neurosci. 894.6).

According to a first aspect, there is provided a compound of formula (I):



wherein:

- A is aryl or 5 to 6 membered heteroaryl optionally substituted by one to five substituents selected from the group consisting of cyano, halo, C₁₋₆-alkyl, C₁₋₆-haloalkyl, C₁₋₆-alkylsulfonyl, or C₁₋₆-alkoxy;
- n is 1, 2, 3 or 4;
- p is 1, 2, 3 or 4;
- q is 1;
- r is 0, 1, 2 or 3;
- R¹ is C₂₋₆-alkenyl or C₂₋₆-alkynyl substituted by aryl,
or is C₁₋₆-alkyl optionally substituted by one to five substituents selected from the group consisting of:
halo,
hydroxy,
C₁₋₆-alkyl,
C₁₋₆-haloalkyl,
-CO(O)-C₁₋₆-alkyl,
C₃₋₁₀-cycloalkyl,
C₁₋₆-alkoxy optionally substituted by one, two or three halo or substituted by aryl,
aryl optionally substituted by halo or C₁₋₆-alkoxy,
5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl, and
phenoxyl,
or is C₁₋₆-alkoxy,
or is C₃₋₁₀-cycloalkyl optionally substituted by one or more R^a,
or is 4 to 10 membered heterocycloalkyl optionally substituted by one or more R^a,
or is aryl optionally substituted by one or more R^a,
or is 5 to 10 membered heteroaryl optionally substituted by one or more R^a,

or is $\text{-NR}^b\text{R}^c$, wherein R^b is H or C_{1-6} -alkyl and wherein R^c is H, C_{1-6} -alkyl or aryl optionally substituted by one or more R^a ,

wherein R^a is selected from:

halo,

cyano,

oxo,

hydroxy,

halobenzenesulfonyl,

C_{1-6} -alkyl optionally substituted by one, two or three substituents selected from the group consisting of:

5 to 10 membered heterocycloalkyl, and

aryl which is optionally substituted by halo or by C_{1-6} -alkoxy,

C_{1-6} -haloalkyl,

C_{1-6} -haloalkoxy,

C_{1-6} -alkoxy optionally substituted by aryl or 5 to 10 membered heteroaryl which is optionally substituted by C_{1-6} -alkyl,

aryloxy,

-NH(CO)-C_{1-6} -alkyl,

-O(CO)-C_{1-6} -alkyl,

C_{1-6} -alkylsulfonyl,

aryl,

4 to 10 membered heterocycloalkyl optionally substituted by hydroxy, C_{1-6} -alkyl or oxo,

5 to 10 membered heteroaryl optionally substituted by C_{1-6} -alkyl or oxo,

and

$\text{di(C}_{1-6}\text{)alkylamino}$;

R^2 is H, OH, C_{1-6} -alkyl or halo;

as well as pharmaceutically acceptable salts thereof.

According to a second aspect, there is provided a medicament containing one or more compounds as defined above and pharmaceutically acceptable excipients for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

According to a third aspect, there is provided a compound as defined above as well as its pharmaceutically acceptable salt for use in the treatment or prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

According to a fourth aspect, there is provided the use of a compound as defined above as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

Compounds of formula (I) may form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, salicylate, sulphate, pyruvate, citrate, lactate, mandelate, tartarate, and methanesulphonate. Preferred are the hydrochloride salts. Also solvates and hydrates of compounds of formula I and their salts form part of the present invention.

Compounds of formula (I) can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically

active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbent or eluant). The invention embraces all of these forms.

It will be appreciated, that the compounds of general formula (I) in this invention
5 may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo. Physiologically acceptable and metabolically labile derivatives, which are capable of producing the parent compounds of general formula I in vivo are also within the scope of this invention.

"Aryl" represents an aromatic carbocyclic group consisting of one individual ring, or
10 one or more fused rings in which at least one ring is aromatic in nature. Preferred aryl group is phenyl or naphthyl, as well as those specifically illustrated by the examples herein below.

"aryloxy" denotes an aryl group as defined hereinabove and the aryl group is connected via an oxygen atom. An example of aryloxy is phenoxy.

15 "C₁₋₆-alkyl" denotes a straight- or branched-carbon chain group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl as well as those specifically illustrated by the examples herein below.


"di(C₁₋₆-alkyl)amino" denotes a nitrogen atom substituted by two C₁₋₆-alkyl groups
20 as defined hereinabove. Examples of di(C₁₋₆-alkyl)amino are dimethylamino, diethylamino, dipropylamino, methylethylamino as well as those groups which are specifically illustrated by the examples herein below.

"C₁₋₆-haloalkyl" denotes a C₁₋₆-alkyl group as defined above which is substituted by one or more halogen. Examples of C₁₋₆-haloalkyl include but are not limited to methyl,
25 ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below. Preferred C₁-C₇-haloalkyl are difluoro- or trifluoro-methyl or ethyl.

"C₁₋₆-alkylsulfonyl" denotes a sulfonyl group (SO₂) which is substituted by a C₁₋₆-alkyl group as defined above.

30 "halobenzenesulfonyl" denotes a group having the following formula:

- 8 -



“C₁₋₆-alkoxy” denotes a group wherein the alkyl group is as defined above and the alkyl group is connected via an oxygen atom.

“C₁₋₆-haloalkoxy” denotes a C₁₋₆-alkoxy group as defined above which is substituted by one or more halogen. Examples of C₁₋₆-haloalkoxy include but are not limited to methoxy or ethoxy, substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below. Preferred C₁-C₇ haloalkoxy are difluoro- or trifluoro-methoxy or ethoxy.

“Halo” or “Halogen” denotes chlorine, iodine, fluorine and bromine.

“C₃₋₁₀-cycloalkyl” denotes a monovalent saturated moiety, consisting of one, two or three carbon rings having 3 to 10 carbon atoms as ring members and includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and polyspiro groups such as bicyclo[2.2.2]octanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.2.1]octanyl or adamantanyl as well as those groups specifically illustrated by the examples herein below.

“5 to 10 membered heteroaryl” means a monocyclic, bicyclic or tricyclic radical of 5 to 10 ring atoms having at least one aromatic ring and furthermore containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C. Heteroaryl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, cyano, alkyl, alkoxy, thioalkyl, halo, haloalkyl, hydroxyalkyl, alkoxycarbonyl, amino, acetyl, -NHCOOC(CH₃)₃ or halogen substituted benzyl, or for the non aromatic part of cyclic ring also by oxo, unless otherwise specifically indicated. Examples of heteroaryl moieties include, but are not limited to, optionally substituted imidazolyl, optionally substituted thiophenyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted pyrazinyl, optionally substituted pyrrolyl, , optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyridazinyl, optionally substituted indolyl, optionally substituted isoindolyl, optionally substituted 2,3-dihydroindolyl, optionally substituted indazolyl, optionally substituted naphthyridinyl, optionally substituted isoquinolinyl, optionally substituted carbazol-9-yl, optionally substituted furanyl,

optionally substituted benzofuranyl, optionally substituted quinoliny, optionally substituted benzo[1,3]dioxolyl, optionally substituted benzo[1,2,3]thiadiazolyl, optionally substituted benzo[b]thiophenyl, optionally substituted 9H-thioxanthenyl, optionally substituted thieno[2,3-c]pyridinyl, optionally substituted 3H-imidazo[4,5,b]pyridinyl, optionally substituted phthalazinyl, optionally substituted 2,3-dihydrobenzo[1,4]dioxinyl, and the like or those which are specifically exemplified herein. Preferred 5 to 10 membered heteroaryls are 5 or 6 membered heteroaryls.

“5 to 10 heterocycloalkyl” means a monovalent saturated moiety, consisting of one, two or three rings, incorporating one, two, or three heteroatoms (chosen from nitrogen, oxygen or sulfur). Heterocycloalkyl can optionally be substituted with one, two, three or four substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, thioalkyl, halo, haloalkyl, hydroxyalkyl, alkoxycarbonyl, amino, alkylamino, dialkylamino, aminocarbonyl, or carbonylamino, unless otherwise specifically indicated. Examples of heterocyclic moieties include, but are not limited to, piperidinyl, piperazinyl, homopiperazinyl, azepinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinuclidinyl, quinoliny, isoquinoliny, benzimidazolyl, chromanyl, thiadiazolylidinyl, benzothiazolidinyl, benzoazolylidinyl, dihydrofuryl, tetrahydrofuryl, dihydropyranly, tetrahydropyranly, thiomorpholinyl, dioxothiomorpholinyl thiomorpholinylsulfoxide, thiomorpholinylsulfone, dihydroquinoliny, dihydroisoquinoliny, tetrahydroquinoliny, tetrahydroisoquinoliny, 1-oxo- thiomorpholin, 1,1-dioxo-thiomorpholin, 1,4-diazepane, 1,4-oxazepane as well as those groups specifically illustrated by the examples herein below. Preferred 5 to 10 membered heterocycloalkyls are 5 or 6 membered heterocycloalkyls.

“one or more” denotes herein, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 and preferably 1, 2, 3, 4 or 5 and still more preferably 1, 2 or 3.


“oxo” denotes a group =O.

“Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.

“Pharmaceutically acceptable salts” of a compound means salts that are pharmaceutically acceptable, as defined herein, and that possess the desired

pharmacological activity of the parent compound. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, p-toluenesulfonic acid, trimethylacetic acid, and the like.

Also encompassed by the compounds of formula (I) are the compounds of formula (Ia):



wherein A, R¹ and R² are as defined hereinabove for formula (I).

Preferred compounds of formula (Ia) are the compounds wherein:

- A is aryl (for example phenyl) or 5 to 6 membered heteroaryl (for example thiophenyl) optionally substituted by one to five substituents selected from the group consisting of halo (for example F or Cl) or C₁₋₆-alkoxy (for example OMe);
- R¹ is C₂₋₆-alkynyl substituted by aryl (for example ethynylphenyl), or is C₁₋₆-alkyl optionally substituted by one to five substituents selected from the group consisting of:
- halo,
 - hydroxy,
 - CO(O)-C₁₋₆-alkyl,
 - C₃₋₁₀-cycloalkyl,
 - C₁₋₆-alkoxy optionally substituted by aryl,
 - aryl optionally substituted by halo or C₁₋₆-alkoxy,
 - 5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl, and
 - phenoxy,
- or is C₁₋₆-alkoxy,

or is C₃₋₁₀-cycloalkyl optionally substituted by one or more R^a and R^a is selected from the group consisting of one, two, three C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, oxo, C₁₋₆-haloalkyl and halo,

or is 4 to 10 membered heterocycloalkyl optionally substituted by one or more R^a and R^a is selected from the group consisting of one, two, three phenyl, phenoxy and C₁₋₆-alkyl,

or is aryl optionally substituted by one or more R^a and R^a is selected from the group consisting of:

cyano,

C₁₋₆-alkyl optionally substituted by 5 to 6 membered heterocycloalkyl,

halo,

C₁₋₆-haloalkyl,

C₁₋₆-haloalkoxy,

C₁₋₆-alkoxy optionally substituted by 5 to 6 membered heteroaryl which is optionally substituted by C₁₋₆-alkyl,

5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl,

4 to 10 membered heterocycloalkyl optionally substituted by hydroxy, by oxo or by C₁₋₆-alkyl,

-NH(CO)-C₁₋₆-alkyl,

halobenzenesulfonyl,

phenyl and

di(C₁₋₆)alkylamino;

or is 5 to 10 membered heteroaryl optionally substituted by one or more R^a and R^a is selected from the group consisting of:

halo,

C₁₋₆-alkyl optionally substituted by aryl which is substituted by halo,

C₁₋₆-alkoxy,

Oxo,

C₁₋₆-haloalkoxy,

C₁₋₆-alkylsulfonyl,

5 to 6 membered heterocycloalkyl optionally substituted by C₁₋₆-alkyl, and

aryl,

or is $-NR^bR^c$, wherein R^b is H or C_{1-6} -alkyl and wherein R^c is H, C_{1-6} -alkyl or aryl optionally substituted by one or more R^a , and R^a is selected from the group consisting of: halo, C_{1-6} -alkyl and C_{1-6} -alkoxy;

R^2 is H, OH, C_{1-6} -alkyl or halo;

5 as well as pharmaceutically acceptable salts thereof.

In a particular embodiment, the compounds of formula (Ia) are those compounds wherein R^1 is 5 to 10 membered heteroaryl optionally substituted by one or more R^a , for example the following compounds:

2-Methyl-2H-indazole-3-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-
10 piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

6-Chloro-2-methyl-quinoline-3-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-
piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Chloro-1-(3,4-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid
trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

15 N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-methyl-
nicotinamide;

[1,8]Naphthyridine-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-
yl]-ethyl}-cyclohexyl)-amide;

5-Fluoro-1H-indole-2-carboxylic acid (trans-4-{2-[4-(4-fluoro-benzoyl)-piperidin-
20 1-yl]-ethyl}-cyclohexyl)-amide;

5-Trifluoromethoxy-1H-indole-2-carboxylic acid (trans-4-{2-[4-(4-fluoro-benzoyl)-
piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Methoxy-1H-indole-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-
1-yl]-ethyl}-cyclohexyl)-amide;

25 Thiophene-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-
ethyl}-cyclohexyl)-amide;

3H-Imidazo[4,5-b]pyridine-6-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-
piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Methanesulfonyl-thiophene-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-
30 piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

6-Fluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-
nicotinamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-
morpholin-4-yl-nicotinamide;

- 3-Methyl-chroman-3-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 2-Morpholin-4-yl-pyrimidine-5-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 5 6-Morpholin-4-yl-pyridazine-3-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 5-Morpholin-4-yl-pyrazine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- Benzo[1,3]dioxole-5-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 10 3-Methyl-isoxazole-5-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- Trans N-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-isonicotinamide;
- 15 N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-morpholin-4-yl-nicotinamide;
- 2,3-Dihydro-benzo[1,4]dioxine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 5-(4-Methyl-piperazin-1-yl)-pyridine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 20 5-Morpholin-4-yl-pyridine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 5-Phenyl-pyridine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 25 Quinoline-4-carboxylic acid trans- (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- Quinoline-4-carboxylic acid trans-(4-{2-[4-(4-methoxy-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- Quinoline-4-carboxylic acid trans-{4-[2-(4-benzoyl-4-hydroxy-piperidin-1-yl)-ethyl]-cyclohexyl}-amide;
- 30 Quinoline-4-carboxylic acid trans-{4-[2-(4-benzoyl-4-fluoro-piperidin-1-yl)-ethyl]-cyclohexyl}-amide;
- Quinoline-4-carboxylic acid trans-(4-{2-[4-(3,4-dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

2,3-Dihydro-indole-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

6-Trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5 1,3-Dihydro-isoindole-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

3,4-Dihydro-1H-isoquinoline-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Quinoline-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-4-hydroxy-piperidin-10 1-yl]-ethyl}-cyclohexyl)-amide;

5-Methanesulfonyl-thiophene-2-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Chroman-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

15 (R)-Chroman-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

(S)-Chroman-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-20 morpholin-4-yl-nicotinamide;

2,3-Dihydro-indole-1-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Quinoline-4-carboxylic acid trans (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

25 5-Methanesulfonyl-thiophene-2-carboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Chroman-3-carboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

30 5-Methanesulfonyl-thiophene-2-carboxylic acid (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Quinoline-4-carboxylic acid (4-{2-[4-(2-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Chroman-3-carboxylic acid (*trans*-4-{2-[4-(4-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Chroman-3-carboxylic acid (*trans*-4-{2-[4-(3-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide; and

Benzo[1,3]dioxole-5-carboxylic acid (*trans*-4-{2-[4-(5-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide.

5

In a particular embodiment, the compounds of formula (Ia) are those compounds wherein R¹ is -NR^bR^c, wherein R^b is H or C₁₋₆-alkyl and wherein R^c is H, C₁₋₆-alkyl or aryl optionally substituted by one or more R^a, for example the following compounds:

Trans 1-(2,4-Dichloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea;

Trans 1-(4-Chloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea;

Trans 1-(4-Ethoxy-phenyl)-3-(4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea;

Trans 1-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-p-tolyl-urea;

Trans 1-(4-Chloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-1-methyl-urea;

Trans- 3-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-1,1-dimethyl-urea;

Trans 1-(4-Chloro-phenyl)-3-(4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea;

Trans 1-(4-Chloro-phenyl)-3-(4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea; and

Trans 1-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(4-ethoxy-phenyl)-urea.

In a particular embodiment, the compounds of formula (Ia) are those compounds wherein R¹ is aryl optionally substituted by one or more R^a, for example the following compounds:

4-Chloro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

4-(3,5-Dimethyl-isoxazol-4-ylmethoxy)-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

30

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-trifluoromethyl-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

5 N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyrrol-1-yl-benzamide;

10 4-Ethoxy-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

4-Acetyl-amino-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl)-benzamide;

15 4-Cyano-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyrazol-1-yl-benzamide;

20 2,4-Dichloro-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

4-(4-Chloro-benzenesulfonyl)-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-trifluoromethoxy-benzamide;

25 N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(1,1,2,2-tetrafluoro-ethoxy)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyridin-3-yl-benzamide;

30 N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyridin-4-yl-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyridin-2-yl-benzamide;

- N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(4-methyl-piperazin-1-yl)-benzamide;
- N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-phthalazin-1-yl-benzamide;
- 5 N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-4-pyridin-2-yl-benzamide;
- Biphenyl-4-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 2-Fluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-10 morpholin-4-yl-benzamide;
- 4-(3,3-Dimethyl-2-oxo-azetidin-1-yl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;
- N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-ylmethyl-benzamide;
- 15 4-tert-Butoxy-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;
- 4-Dimethylamino-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;
- 4-(1,1-Dioxo-6-thiomorpholin-4-yl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;
- 20 1-yl]-ethyl}-cyclohexyl)-benzamide;
- 3-Fluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;
- N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(3-hydroxy-pyrrolidin-1-yl)-benzamide;
- 25 N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(4-hydroxy-piperidin-1-yl)-benzamide;
- N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-thiomorpholin-4-yl-benzamide;N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-piperidin-1-yl-benzamide;
- 30 N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-morpholin-4-yl-benzamide;
- N-trans (4-{2-[4-(4-Fluoro-benzoyl)-4-hydroxy-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;
- N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-35 ethoxy-benzamide;

N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;

4-Chloro-N-(4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

5 Biphenyl-4-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

N-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

4-Cyano-N-trans (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-
10 benzamide;

N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyrrol-1-yl-benzamide;

N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

15 N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

4-Chloro-N-trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans (4-{2-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-
20 morpholin-4-yl-benzamide; and

N-(trans-4-{2-[4-(4-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide.

In a particular embodiment, the compounds of formula (Ia) are those compounds wherein R¹ is C₃₋₁₀-cycloalkyl optionally substituted by one or more R^a, for example the
25 following compounds:

Cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

30 Adamantane-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

2-Cyclopropyl-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

2-Methyl-cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-
35 1-yl]-ethyl}-cyclohexyl)-amide;

- 4-Methoxy-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 4-Hydroxy-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 5 (1S,4R)-Bicyclo[2.2.1]heptane-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- (1R,4R)-7,7-Dimethyl-2-oxo-bicyclo[2.2.1]heptane-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 4-Trifluoromethyl-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 10 1-Methyl-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 4-Methyl-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 15 6-Hydroxy-bicyclo[2.2.2]octane-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 1-Trifluoromethyl-cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 3-Chloro-cyclobutanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 20 1-Hydroxy-cyclopropanecarboxylic acid (trans-4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- Cyclobutanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 25 4-Hydroxy-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 2,2-Difluoro-cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- Cyclopropanecarboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 30 Cyclobutanecarboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;
- 4-Trifluoromethyl-cyclohexanecarboxylic acid trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Cyclopropanecarboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

2,2-Difluoro-cyclopropanecarboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide; and

- 5 Cyclopropanecarboxylic acid trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide.

In a particular embodiment, the compounds of formula (Ia) are those compounds wherein R¹ is 5 to 10 membered heterocycloalkyl optionally substituted by one or more R^a,
10 for example the following compounds:

Tetrahydro-pyran-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-furan-3-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

- 15 Morpholine-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

3-Phenoxy-pyrrolidine-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

- 20 1,1-Dioxo-thiomorpholine-4-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-furan-3-carboxylic acid trans-(4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-furan-3-carboxylic acid trans-(4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

- 25 (S)-Tetrahydro-furan-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

(R)-Tetrahydro-furan-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

- 30 4-Phenyl-piperazine-1-carboxylic acid trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Morpholine-4-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Pyrrolidine-1-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-furan-3-carboxylic acid trans (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-pyran-4-carboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5 Tetrahydro-furan-3-carboxylic acid trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-pyran-4-carboxylic acid (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide; and

10 Tetrahydro-pyran-4-carboxylic acid (*trans*-4-{2-[4-(4-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide.

In a particular embodiment, the compounds of formula (Ia) are those compounds wherein R^1 is C_{1-6} -alkyl optionally substituted by one to five substituents selected from the group consisting of:

- 15 halo,
hydroxy,
 C_{1-6} -alkyl,
-CO(O)- C_{1-6} -alkyl,
 C_{3-10} -cycloalkyl,
20 C_{1-6} -alkoxy optionally substituted by one, two or three halo or substituted by aryl,
aryl optionally substituted by halo or C_{1-6} -alkoxy,
5 to 10 membered heteroaryl optionally substituted by C_{1-6} -alkyl, and
phenoxyl,

for example the following compounds:

25 N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;

2-(4-Chloro-phenyl)-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-isobutyramide;

3-Ethoxy-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-
30 propionamide;

3,3,3-Trifluoro-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide;

- 2,2,2-Trifluoro-N-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;
- N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-butyramide;
- N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-
- 5 butyramide;
- N-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-phenoxy-propionamide;
- N-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-hydroxy-2,2-dimethyl-propionamide;
- 10 2-Benzo[d]isoxazol-3-yl-N-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;
- N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide;
- 2-(3,5-Dimethoxy-phenyl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;
- 15 2-Benzo[1,3]dioxol-5-yl-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;
- Acetic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexylcarbamoyl)-methyl ester;
- 20 N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;
- N-trans (4-{2-[4-Fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;
- N-trans (4-{2-[4-Fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
- 25 Trans N-(4-{2-[4-(4-Fluoro-benzoyl)-4-methyl-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;
- N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
- N trans -(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-
- 30 propionamide;
- N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;
- N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide;

N-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-hydroxy-acetamide;

(R)-N-Trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-propionamide;

5 2-Benzyloxy-N-trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-butyramide;

10 2-Cyclopropyl-N-(4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide;

2-Benzyloxy-N-trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

15 N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-butyramide;

N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-cyclopropyl-acetamide;

20 N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide;

N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;

N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

25 N-trans (4-{2-[4-(2-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-Trans (4-{2-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-Trans (4-{2-[4-(2,5-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

30 N-Trans (4-{2-[4-(4-Fluoro-2-methyl-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-{trans-4-[2-(4-Benzoyl-piperidin-1-yl)-ethyl]-cyclohexyl}-acetamide;

N-(trans-4-{2-[4-(3-Chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-(trans-4-{2-[4-(5-Chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-(trans-4-{2-[4-(5-Fluoro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide.

5


In a particular embodiment, the compounds of formula (Ia) are those compounds wherein R^1 is C_{1-6} -alkoxy, for example the following compounds:

Trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid methyl ester; and

10 4-Ethoxy-N-trans (4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide.

In a particular embodiment, the compounds of formula (Ia) are those compounds wherein R^1 is C_{2-6} -alkenyl or C_{2-6} -alkynyl substituted by aryl, for example the following
15 compound: 3-Phenyl-propynoic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide.

Also encompassed by the compounds of formula (I) are the compounds of formula (Ib):



20


wherein A, R^1 and R^2 are as defined hereinabove for formula (I), for example the following compounds:

N-{Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;

25 2-(4-Chloro-phenyl)-N-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-isobutyramide; and

1-(4-Chloro-phenyl)-3-{trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-urea.

Also encompassed by the compounds of formula (I) are the compounds of formula (Ic):



wherein A, R¹ and R² are as defined hereinabove for formula (I), for example the following compounds:


N-{Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;

2-(4-Chloro-phenyl)-N-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-isobutyramide;

4-Chloro-N-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-benzamide; and

1-(4-Chloro-phenyl)-3-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-urea.

Also encompassed by the compounds of formula (I) are the compounds of formula (Id):



wherein A, R¹ and R² are as defined hereinabove for formula (I), for example the following compounds:

4-Ethoxy-N-4-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-butyl}-benzamide;

N-{4-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-butyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;


Tetrahydro-furan-3-carboxylic acid {4-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-butyl}-amide;

1-(4-Chloro-phenyl)-3-{4-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-butyl}-urea; and

1-(4-Ethoxy-phenyl)-3-{4-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-butyl}-urea.

Further aspect of the present invention are pharmaceutical compositions containing the compounds of formulae (I), (Ia), (Ib), (Ic) and (Id) schizophrenia, cognitive disorders and drug addiction.

A further aspect of the present invention is the process for the manufacture of
5 compounds of formula (Ia) as defined above, which process comprises reacting a compound of the formula II:




wherein A and R² are as defined hereinabove,

a) either with an acid of the formula III:



in the presence of a coupling reagent such as O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) in a suitable solvent like, e.g. dimethylformamide (DMF) or dioxane in the presence of a base (e.g. triethylamine or diisopropylethylamine) to obtain a compound of the formula (Ia):



wherein:

R¹ is C₂₋₆-alkenyl or C₂₋₆-alkynyl substituted by aryl,

or is C₁₋₆-alkyl optionally substituted by one to five substituents selected from the group consisting of:

20 halo,

hydroxy,

C₁₋₆-alkyl,

-CO(O)-C₁₋₆-alkyl,

C₃₋₁₀-cycloalkyl,

25 C₁₋₆-alkoxy optionally substituted by one, two or three halo or substituted by aryl,
aryl optionally substituted by halo or C₁₋₆-alkoxy,

5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl, and phenoxy,

or is C₁₋₆-alkoxy,


or is C₃₋₁₀-cycloalkyl optionally substituted by one or more R^a,

5 or is 5 to 10 membered heterocycloalkyl optionally substituted by one or more R^a,

or is aryl optionally substituted by one or more R^a,

or is 5 to 10 membered heteroaryl optionally substituted by one or more R^a,

10 b) or with an isocyanate or a reactive intermediate such as para nitrophenyl carbamate in a suitable solvent like, e.g. dimethylformamide (DMF) or acetonitrile in the presence of a base (e.g. triethylamine or diisopropylethylamine) to obtain a compound of the formula (Ia):



wherein

15 R¹ is -NR^bR^c, wherein R^b is H or C₁₋₆-alkyl and wherein R^c is H, C₁₋₆-alkyl or aryl optionally substituted by one or more R^a;

or is 5 to 10 membered heterocycloalkyl containing a nitrogen atom attached to the carbonyl group of (Ia) to which R¹ is attached, optionally substituted by one or more R^a,

20 or is 5 to 10 membered heteroaryl containing a nitrogen atom attached to the carbonyl group of (Ia) to which R¹ is attached, optionally substituted by one or more R^a

and if desired,

converting the compound obtained into a pharmaceutically acceptable acid addition salt.


25 The preparation of compounds of formula (I) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those skilled in the art. The substituents and indices used in the following description of the processes have the significance given

30 herein before unless indicated to the contrary.

In more detail, the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Starting materials are either commercially available or can be prepared by methods
 5 analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.

In the following schemes, A, R¹ and R² are as described hereinabove.


Scheme 1



10 Heteroaryl or benzoyl-piperidin-1-yl trans -ethyl-cyclohexyl-amides or trans-1,4-cyclohexyl ethyl derivatives of formula (Ia) can be prepared as depicted in scheme 1 starting from 4-nitro-phenylacetic acid that was hydrogenated using raney nickel as catalyst. The hydrogenation with nickel leads preferentially to the desired trans-isomer (according to
 15 Journal of Medicinal Chemistry, 1998, 41, 760-771). Preparing the ethyl ester according to methods known to those skilled in the art and described in the mentioned literature (e.g by treatment with ethanol on the presence of an acid such as HCl) and crystallizing the HCl salt resolves the cis/trans mixture and results in the isolation of the pure trans amino ester


chloride B. Reaction with a protecting group such as tert-butyl dicarbonate on the presence of a base like triethylamine and a catalyst like dimethylaminopyridine and reduction with diisobutylaluminium hydride (DIBAL-H) in an appropriate solvent such as, e.g. toluene at -78 °C gives the aldehyde C which can be used without purification on the next step. Reductive amination of aldehyde C with a substituted phenyl or heteroaryl piperidin-4-yl-methanone D either commercially available or accessible by methods described in references by methods described in this patent or by methods known in the art in the presence of a solvent like dichloromethane or 1,2-dichlorethane and a reducing agent such as sodium triacetoxy borohydride yields intermediate E. Removal of the Boc protective group under acidic conditions such as trifluoroacetic acid or hydrochloric acid in a suitable solvent such as, e.g. THF, EtOAc or dichloromethane yields the *trans*-amino cyclohexyl ethyl intermediate F (usually the TFA or hydrochloride salt). The coupling of the amine intermediate F with carboxylic acids (either commercially available or accessible by methods described in references or by methods known in the art) is widely described in literature (e.g. Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY. 1999) and can be accomplished by employing the usage of coupling reagents such as, e.g. N,N'-carbonyldiimidazole (CDI) or O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) in a suitable solvent like, e.g. dimethylformamide (DMF) or dioxane in the presence of a base (e.g. triethylamine or diisopropylethylamine) to yield compounds of formula (Ia). In other cases an acid chloride can also be used in the presence of a base (e.g. triethylamine or diisopropylethylamine) in a solvent like dichloromethane.

Scheme 2



- In other examples the intermediate F can also react with an isocyanate (when R^c=H) or a reactive intermediate (R^c≠H) such as an appropriate commercial available acid chloride or a para nitro carbamate prepared by methods known in the art or using triphosgene in the presence of a suitable solvent like, e.g. acetonitrile or dichloromethane and of a base (e.g. triethylamine or diisopropylethylamine) to obtain a compound of the formula (Ia) as described on the scheme 2 above.

Scheme 3




In some cases the phenyl or heteroaryl piperidin-4-yl-methanone **D** can be coupled in a reductive amination step with a more elaborated aldehyde **I** according to scheme 3. We used in some cases the quinoline-4-carboxylic acid [4-(2-oxo-ethyl)-cyclohexyl]-amide.

- 5 The preparation of quinoline-4-carboxylic acid [4-(2-oxo-ethyl)-cyclohexyl]-amide **I** is described on scheme 2 starting from 4-nitro-phenylacetic acid **A** that was hydrogenated as already described on scheme 1 using raney nickel and preparing the trans-amino ethyl ester chloride **B** as already also described on scheme 1. In this case instead of performing the reaction with a protecting group installing reagent such as tert-butyl dicarbonate the amine
- 10 or amine hydrochloride can reacted with quinoline-4-carbonyl chloride in the presence of a base such as triethylamine in solvent such as dichloromethane to obtain trans-{4-[(quinoline-4-carbonyl)-amino]-cyclohexyl}-acetic acid ethyl ester. Hydrolysis of the ester function under acid or basic conditions such as lithium hydroxide in a solvent mixture such as THF: water gives the corresponding acid **G**. The preparation of acid intermediates
- 15 in order to make reductions is known in literature (e.g. T. Fukuyama et.al., Synthesis 2000, 8, 1121-1123). In this case reaction of the acid with sodium ethylthiolate prepared previously from ethanethiol and a base such as butyllithium in a solvent such as dimethoxyethane yields trans-{4-[(quinoline-4-carbonyl)-amino]-cyclohexyl}-thioacetic acid S-ethyl ester (**H**) that can be reduced with palladium on charcoal and triethylsilane in

a solvent like acetone/methylenechloride (1:1) mixture to obtain the desired trans-quinoline-4-carboxylic acid [4-(2-oxo-ethyl)-cyclohexyl]-amide (I) that can be used in a reductive amination using a reducing agent such as sodium triacetoxy borohydride in a solvent such as dichloromethane to obtain directly trans-quinoline-4-carboxylic acid (4-{2-

5 [4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl]-cyclohexyl)-amide (Ia).

Scheme 4




Compounds of the general formula (Ic) wherein R¹ is NR^bR^c or different from NR^bR^c can also be prepared according to scheme 4. In this case the intermediate N used on the reductive amination with the phenyl or heteroaryl piperidin-4-yl-methanone is prepared starting from ethyl 2-formyl-1-cyclopropanecarboxylate (88-90% trans isomer) that can react in a reductive BOC amination (known in literature e.g. Tetrahedron Letters 42 (2001), 5093-5094) through the formation of an α -amidoalkyl sulfone K using tert butyl carbamate and anhydrous sodium p-toluenesulfinate in solvents like methanol and water.

15 The α -amidoalkyl sulfone K is crystallized in a solvent like n-heptane to obtain only the trans isomer. Reaction of the α -amidoalkyl sulfone intermediate K with sodium borohydride in a solvent like tetrahydrofuran produces the trans-2-(tert-butoxycarbonylamino-methyl)-cyclopropanecarboxylic acid ethyl ester L through the

- formation of an imine as intermediate. Reduction of the ethyl ester M with a reducing agent such as diisobutylaluminium hydride (DIBAL-H) in an appropriate solvent such as, e.g. toluene at -78 °C gives the aldehyde M which can be used without purification on the next step. Reductive amination of the aldehyde with a substituted phenyl or heteroaryl
- 5 piperidin-4-yl-methanone D in the presence of a solvent like 1,2-dichloromethane and a reducing agent such as sodium triacetoxy borohydride yields intermediate N. Removal of the Boc protective group under acidic conditions such as trifluoroacetic acid in a suitable solvent such as, e.g. THF yields an intermediate (usually as a salt) that as in scheme1 can be coupled with carboxylic acids using a coupling agent such as O-benzotriazol-1-yl-
- 10 N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) in a suitable solvent like, e.g. dimethylformamide (DMF) or dioxane in the presence of a base (e.g. triethylamine or diisopropylethylamine) yielding compounds of formula (Ic) wherein R^1 is not NR^bR^c . In the cases where R^1 is NR^bR^c the intermediate mentioned above could react with an isocyanate yielding the corresponding compounds of formula (Ic).


15

Scheme 5




- Compounds of the general formula (Ib) wherein R^1 is NR^bR^c and (Ib) wherein R^1 is not NR^bR^c and wherein can be also prepared according to scheme 5 through an alkylation step with an adequate good leaving group installed on the coupling partner. This coupling partner T (methanesulfonic acid trans-(tert-butoxycarbonylamino-methyl) cyclobutylmethyl ester) can be obtained from the commercial available trans-cyclobutanedicarboxylic acid dimethyl ester O that is reduced to the trans-2-hydroxymethyl-cyclobutanecarboxylic acid methyl ester P with the use of a reducing agent such as sodium borohydride in a solvent like methanol. Oxidation of the alcohol functionality according to methods known to those skilled in the art and described in literature (e.g. under Swern conditions using oxalyl chloride, dimethylsulfoxide and triethylamine in a solvent such as dichloromethane) yields intermediate Q that follows the same step of reductive BOC amination through the formation of an α -amidoalkyl sulfone intermediate already described on scheme 4. Reduction of the ethyl ester S to the alcohol T with a reducing agent such as sodium borohydride and conversion of the alcohol into a good leaving group (e.g. conversion to a mesylate T by reaction with methanosulphonyl chloride in the presence of a base such as N,N-diisopropylethylamine and in a solvent like dichloromethane) that reacts in an alkylation step with a substituted phenyl or heteroaryl piperidin-4-yl-methanone D in presence of a base (e.g N,N-diisopropylethylamine) under refluxing conditions gives intermediates of structure N. The last two steps (removal of the Boc protecting group and amide or urea formation) are the same that the ones already described for schemes 1, 2 and 4.

Scheme 6




The phenyl or heteroaryl piperidin-4-yl-methanone D intermediates where R² signifies OH can be prepared according to scheme 6 and following a process also partially described in literature (e.g. patent DE 25365103). Introduction of a benzyl group using benzyl bromide in the presence of a base like triethylamine with or without a catalyst such as sodium iodide in a solvent like acetonitrile using a temperature such as 80 °C gave intermediate W. Introduction of bromide in alpha position to the ketone of (1-benzyl-piperidin-4-yl)-(4-fluoro-phenyl)-methanone can be accomplished using bromine under reflux. Treatment of the alpha bromo ketone X with sodium methanolate gave 6-benzyl-2-(4-fluoro-phenyl)-2-methoxy-1-oxa-6-aza-spiro[2.5]octane (Y) that can be hydrolyzed in a solvent like ether under chloridic acid treatment to yield (1-benzyl-4-hydroxy-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (Z). Removal of the benzyl group can be performed under hydrogenation conditions using palladium as catalyst in a solvent like ethyl acetate and methanol to obtain the desired (1-benzyl-4-hydroxy-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (intermediate D). On the last hydrogenation step the reduction of the ketone can also be observed and the diol compound can be formed as a side product.

Scheme 7

- The phenyl or heteroaryl piperidin-4-yl-methanone D intermediates where R² signifies a fluorine atom can be prepared according to scheme 7. The phenyl or heteroaryl piperidin-4-yl-methanone might be protected first with a suitable protective group such as a tert-butoxycarbonyl group which, after introduction of the fluorine atom, can be removed under conditions known to those skilled in the art (e.g. treatment with an acid such as trifluoroacetic acid in a suitable solvent such as dichloromethane). The introduction of fluor can be performed by deprotonation of the corresponding carbon in alpha position to the ketone by treatment with a base in a suitable solvent under anhydrous conditions (e.g. potassium ter-butoxide/ t-butanol in DMF) in the presence of a fluorinating agent such as N-fluorobenzenesulphonimide at a temperature from 0 °C to room temperature to obtain after the three steps the aryl-(4-fluoro-piperidin-4-yl)-methanone or heteroaryl-(4-fluoro-piperidin-4-yl)-methanone D.

Scheme 8




The phenyl or heteroaryl piperidin-4-yl-methanone D intermediates where R^2 signifies a methyl or other C_{1-6} -alkyl groups can be prepared according to scheme 8 with a carbon-carbon coupling reaction where a Pd complex catalyzes the acylation of boronic acids with carboxylic anhydrides obtained in situ using pivalic anhydride that reacts with the corresponding N-Boc-4-methyl-4-piperidinecarboxylic acid and using the


5 corresponding phenyl boronic acid. The tert-butoxycarbonyl protecting group can be removed under conditions known those skilled in the art (e.g. treatment with an acid such as trifluoroacetic acid in a suitable solvent such as dichloromethane) to obtain after the

10 three steps the aryl-(4-methyl -piperidin-4-yl)-methanone D.

Scheme 9




Compounds of the general formula (Id) wherein R¹ is NR^bR^c and compounds of formula (Id) wherein R¹ is not NR^bR^c can be prepared according to scheme 9 with a compound D phenyl or heteroaryl piperidin-4-yl-methanone that can be alkylated with 4-(Boc-amino) butyl bromide with the use of a base (e.g N,N-diisopropyl ethyl amine) in an appropriate solvent like acetonitrile under refluxing conditions. After removal of the amine protecting group (in our case the Boc group) using acidic conditions (e.g trifluoroacetic acid in a solvent such as dichloromethane) and as already described, the amine intermediate can be coupled with carboxylic acids using a coupling agent such as O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) in a suitable solvent like, e.g. dimethylformamide (DMF) in presence of a base (e.g. triethylamine or diisopropylethylamine) yielding compounds of formula (Id) wherein R¹ is not NR^bR^c or in other cases with an isocyanate yielding the corresponding compounds of formula (Id) wherein R¹ is NR^bR^c.




Acetic acid amide derivatives of structure AH can be conveniently prepared according to scheme 10 starting from compound B. The reaction sequence involves in a first step the treatment of compound B with AcCl in presence of a base such as Et₃N in a solvent such as CH₂Cl₂ to obtain a compound of formula AE. Reduction with a reagent such as LiAlH₄ in a solvent such as CH₂Cl₂ at 0 °C provides a compound of formula AF. Among several oxidation conditions known in the literature, the *Swern* oxidation (A. Mancuso, D. Swern, *Synthesis* 1981, 165-185) of alcohol AF provides intermediate AG. Reaction of aldehyde AG with an appropriate substituted piperidine in the presence of a reducing agent such as Na(AcO)₃BH in a solvent such as 1,2-dichloroethane provides compounds of formula AH.

Scheme 11



Compounds of formula Ia where A is a substituted or unsubstituted thiophenyl group can be prepared as described in Scheme 1 using a piperidin-4-yl-thiophen-2-yl-methanone of formula AL as intermediate D. The preparation of intermediates of formula AL is depicted in Scheme 11. A thiophene of formula AI can be deprotonated with a base such as *n*-BuLi in a solvent such as THF and reacted with 4-formyl-piperidine-1-carboxylic acid *tert*-butyl ester to obtain an alcohol of formula AJ. Oxidation of an alcohol of formula AJ with reagents such as for example TPAP/NMO or MnO₂ in a solvent such as CH₂Cl₂ affords a ketone of formula AK. Treatment of a compound of formula AK with an acid such as HCl affords a compound of formula AL.

Scheme 12



A compound of structure AL (Scheme 11) where R equals 5-fluoro can be prepared according to scheme 12. This method consists in the subsequent double deprotonation of thiophene with a base such as *n*-BuLi in a solvent such as THF and reaction with a fluorinating agent such as *N*-fluorodibenzene-sulfonimide after the first deprotonation step and 4-formyl-piperidine-1-carboxylic acid *tert*-butyl ester after the second, to obtain an alcohol of formula AM.

The ability of the compounds to bind to the 5-HT_{2A}, D₃ and D₂ receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.

Membrane preparation for human D₂, human D₃ and human 5-HT_{2A} receptors

HEK-293 EBNA cells were transiently transfected with expression plasmids encoding for the human D₂ or D₃ dopamine- or for the human 5-HT_{2A} serotonin receptor, respectively. The cells were harvested 48 h post-transfection, washed three times with cold

PBS and stored at -80°C prior to use. The pellet was suspended in cold 50 mM Tris-HCl buffer containing 10 mM EDTA (pH 7.4) and homogenized with a Polytron (Kinematica AG, Basel, Switzerland) for 20-30 sec at 12.000 rpm. After centrifugation at 48.000 X g for 30 min at 4°C, the pellet was resuspended in cold 10 mM Tris-HCl buffer containing 0.1 mM EDTA (pH 7.4), homogenized, and centrifuged as above. This pellet was further resuspended in a smaller volume of ice cold 10 mM Tris-HCl buffer containing 0.1 mM EDTA (pH 7.4) and homogenized with a Polytron for 20-30 sec at 12.000 rpm. The protein content of this homogenate was determined with the Bio-Rad (Bradford) Protein Assay (Biorad Laboratories GmbH, München, Germany) according to the instructions of the manufacturer using gamma globulin as the standard. This homogenate was stored at -80°C in aliquots and thawed immediately prior to use.

Radioligand binding assay conditions

Aliquots of membrane preparations were thawed at RT, resuspended in assay buffer (D₂, D₃: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl₂, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl₂, pH=7.4; 5-HT_{2A}: 50 mM Tris-HCl, 10 mM MgCl₂, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 µg protein / well (D₂, D₃) and 15 µg protein / well (5-HT_{2A}), respectively.

The binding affinity (K_i) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 µl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [³H]-spiperone for D₂, 0.5 nM [³H]-spiperone for D₃, and 1.1 nM [³H]-ketanserin for 5-HT_{2A}) and ten concentrations of test compound in ranging between 10 µM – 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters (Packard BioScience, Zürich, Switzerland; preincubated for 1 h in 0.1% polyethylenimine (PEI) in assay buffer) with a Filtermate 196 harvester (Packard BioScience) and washed 3 times with cold assay buffer. The nonspecific binding was determined with equally composed reaction mixtures in the presence of 10 µM unlabelled spiperone. Per well 45 µl of Microscint 40 (Perkin Elmer, Schwerzenbach, Switzerland) was added, plates for sealed, shaken for 20 min and counted for 3 min on a Topcount Microplate Scintillation Counter (Canberra Packard SA, Zürich, Switzerland) with quenching correction.

Data calculation

The CPM value for each duplicate of a concentration of competing compound was averaged (y1), then the % specific binding was calculated according to the equation $((y1 - \text{non-specific}) / (\text{total binding} - \text{non-specific})) \times 100$. Graphs were plotted with the % specific binding using XLfit, a curve fitting program that iteratively plots the data using Levenburg Marquardt algorithm. The single site competition analysis equation used was $y = A + ((B - A) / (1 + ((x/C)^D)))$, where y is the % specific binding, A is the minimum y, B is the maximum y, C is the IC_{50} , x is the $\log_{10}$ of the concentration of the competing compound and D is the slope of the curve (the Hill Coefficient). From these curves the IC_{50} (inhibition concentration at which 50% specific binding of the radioligand was displaced) and Hill coefficient were determined. The affinity constant (K_i) was calculated using the Cheng-Prusoff equation $K_i = (IC_{50} / (1 + ([L]/K_d)))$, where [L] is the concentration of radioligand and K_d is the dissociation constant of the radioligand at the receptor as determined by the saturation isotherm.

The compounds of the present invention are selective dual modulators of the serotonin 5-HT_{2a} and dopamine D₃ receptors as this is shown with the activity table hereinafter which gives the K_i values in nM for the serotonin 5-HT_{2a}, dopamine D₃ and dopamine D₂ receptors for some examples of the compounds of the present invention:

Activity table

Example	9	20	22	23
Ki(nM)				
D ₃ /5HT _{2A} /D ₂	6/2/106	18/5/586	15/4/149	72/5/73
Example	29	33	25	41
Ki(nM)				
D ₃ /5HT _{2A} /D ₂	32/8/450	110/65/1977	13/269/777	4/11/677
Example	46	50	57	58
Ki(nM)				
	15/2/30	29/2/288	53/21/1334	19/80/3542

D ₃ /5HT _{2A} /D ₂				
Example	61	64	70	72
Ki(nM) D ₃ /5HT _{2A} /D ₂	35/64/2895	4/26/3998	97/22/2714	39/26/2133
Example	14	26	29	30A25
Ki(nM) D ₃ /5HT _{2A} /D ₂	144/12/96	17/14/684	37/8/450	26/5/1285
Example	30A27	30A28	30A29	30A36
Ki(nM) D ₃ /5HT _{2A} /D ₂	8/8/1117	9/5/470	207/25/1008	26/5/1285
Example	30A37	30A58	30A59	30A64
Ki(nM) D ₃ /5HT _{2A} /D ₂	29/11/2002	30/15/2070	19/5/888	19/13/625
Example	34	39	40	42
Ki(nM) D ₃ /5HT _{2A} /D ₂	23/6/192	2/3/1844	8/9/502	146/11/352
Example	42A7	63A14	65A11	
Ki(nM) D ₃ /5HT _{2A} /D ₂	86/26/176	44/83/8539	71/38/1447	

The compounds of formula I and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical

preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

5 The compounds of formula I and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such as carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for
10 example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection
15 solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

 In addition, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying
20 the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

 As mentioned earlier, medicaments containing a compound of formula I or pharmaceutically acceptable salts thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments
25 which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.

 The dosage can vary within wide limits and will, of course, be fitted to the individual
30 requirements in each particular case. In general, the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described. The daily dosage for an adult human being

weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and 700 mg per day.

The following examples are provided to further elucidate the invention:

Experimental procedures

5 Example 1

4-Chloro-N-trans-(4-[2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl]-cyclohexyl)-benzamide

Intermediate B

Trans-(4-Amino-cyclohexyl)-acetic acid ethyl ester

10 Step 1.

(4-Nitro-phenyl)-acetic acid (50g, 276 mmol) was added to a stirred solution of 22.08g of 50% sodium hydroxide solution in 450mL deionized water. The clear yellow solution is transferred into a high-pressure autoclave that it charged with 30g (511 mmol) of water-wet sponge nickel catalyst. The autoclave is sealed, flushed with nitrogen and then
15 pressurized to 115 bar with hydrogen. The reaction mixture is stirred and heated to 125°C for 48h. At that time the autoclave is cooled, vented and charged under nitrogen with another 30g (511 mmol) of the sponge nickel catalyst. The autoclave is flushed again with nitrogen and then pressurized to 115 bar and the vessel is heated to 130°C while stirring (a maximum pressure of 130 bars is observed). Hydrogenation is continued for 5 days to
20 130°C. The autoclave is then cooled, vented and flushed with nitrogen and the contents are removed and filtered through filter aid to remove catalyst. After removal of the solvent 74g of crude material was obtained. The intermediated is used directly in the next step without purification. MS (m/e): 158.3 (M+H⁺)

25 step 2

A solution of the Trans-(4-amino-cyclohexyl)-acetic acid obtained (74g, 476mmol) was adjusted to pH 5 with 25% HCl. The mixture was evaporated to dryness and dried under vacuum overnight. The residue was suspended in 146mL of a 6.5N ethanolic HCl solution and 0.6L of ethanol was added to the mixture. After 4 h refluxing, the mixture was cooled

and filtered and the filtrate was concentrated to dryness under vacuum. The residue was dissolved in ethanol, treated with ether and cooled overnight in the refrigerator to give the Trans-(4-Amino-cyclohexyl)-acetic acid ethyl ester hydrochloride (19.7 g, 32% on the two steps) as a white solid which was filtered and dried under vacuum. MS (m/e): 186.1

5 (M+H⁺)

Intermediate C

Step 1

Trans-(4-tert-Butoxycarbonylamino-cyclohexyl)-acetic acid ethyl ester

To a solution of Trans-(4-Amino-cyclohexyl)-acetic acid ethyl ester (1.28 g, 7 mmol), in
10 dichloromethane (15mL), di-tert-butyl-dicarbonate (2.26 g, 10mmol), triethylamine (0.699 mL, 7mmol) and 4-dimethylaminopyridine (0.042mL, 0.35mmol) were added. The mixture was stirred for 8h until TLC indicated completion of the reaction. Water was added and the solution was extracted three times with dichloromethane. The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered
15 and evaporated. The crude product was purified by flash-chromatography on silica gel with hexane : ethyl acetate (4:2 to 3:2) to give 1.2 g (60%) of the product as a white solid. MS (m/e): 284.4 (M-H⁺).

Step 2

Trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester

To a solution of trans-(4-tert-Butoxycarbonylamino-cyclohexyl)-acetic acid ethyl ester (1.04 g, 4 mmol), in toluene (10 mL) at -78°C a 1.2M solution of DIBAL-H (5.1mL, 6 mmol) in toluene was added. The mixture was stirred at -78°C until TLC after 0.5h indicated completion of the reaction. Water was added and the solution was extracted three times with dichloromethane. The combined organic layers were washed with water and
25 brine, dried over magnesium sulfate, filtered and evaporated. The crude product was used without purification on the next step. MS (m/e): 242.3 (M+H⁺).

Intermediate E

Trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester

30 A mixture of 4-(4-fluorobenzoyl) piperidine (0.850g, 3.4 mmol), Trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester (0.926 g, 4 mmol), in 1, 2 dichloroethane (10mL)

was stirred for 4 h at room temperature and sodium triacetoxyborohydride (1.33 g, 6 mmol) was added and the resulting solution was stirred for 12 hours until the TLC indicated completion of the reaction. The mixture was filtrated and concentrated to dryness and purified with column chromatography on silica gel using CH_2Cl_2 - CH_2Cl_2 /MeOH (1-9:1). The product fractions were concentrated to give 1.4 g (3.25 mmol, 93.2% yield) of a light yellow solid. MS (m/e): 433.4 (M+H⁺).

Intermediate F

Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (could be obtained as the trifluoroacetic acid salt)

1.4 g (3.25 mmol) of (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester is solved in dichloromethane (30mL) and trifluoroacetic acid is added at 0°C (1.98 mL, 26mmol) and the mixture is stirred at room temperature overnight. NaHCO₃ is slowly added until pH 9 and the mixture extracted with 3 times with dichloromethane and ethyl acetate. The solvent was evaporated to yield 0.812g (24.4mmol, 75.5%) of a white solid that was used without purification on the next steps. MS (m/e): 333.2 (M+H⁺).

4-Chloro-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide

4-chloro benzoic acid (0.014 g, 0.09 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate (0.029 g, 0.09 mmol) and (0.06 mL, 0.270 mmol) of N-ethyl-diisopropylamine were stirred in 0.3mL of DMF for 0.5h at room temperature and Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) (0.030 g, 0.09 mmol) was added. The mixture was stirred for 12 hours at room temperature. The mixture was concentrated to dryness and the residue was taken up on methanol and purified with preparative HPLC on reversed phase eluting with acetonitrile/water. The combined producted fractions were evaporated under reduced pressure to yield 0.015 g of a off-white solid (0.032 mmol, 36%). MS (m/e): 471.3 (M+H⁺).

According to the procedure described for the synthesis of example 1 further derivatives have been synthesized from the respective Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and the corresponding acid. They comprise examples 1 to 30A63 .

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
1	4-Chloro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	471.0	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-chloro benzoic acid	471.3
2	Cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	400.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and Cyclopropanecarboxylic acid	401.3
3	4-(3,5-Dimethyl-isoxazol-4-ylmethoxy)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	561.7	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-(3,5-Dimethyl-isoxazol-4-ylmethoxy)-benzoic acid	562.3
4	Tetrahydro-pyran-4-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	444.59	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and Tetrahydro-pyran-4-	445.3

			carboxylic acid	
5	N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-trifluoromethyl-benzamide	504.57	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-(trifluoromethyl) benzoic acid	505.2
6	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide	418.55	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 3-methoxy-propionic acid	419.3
7	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide	521.68	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-morpholino benzoic acid	522.5
8	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide	518.3	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 3-(5-methyl-1,2,4-oxadiazol-3-yl)-benzoic acid	519.4
9	N-trans (4-{2-[4-(4-		Trans-{1-[2-(4-Amino-	

	Fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-4-pyrrol-1-yl-benzamide	501.65	cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-(1H-pyrrol-1-yl) benzoic acid	502.1
10	4-Ethoxy-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	480.62	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-Ethoxybenzoic acid	481.4
11	Tetrahydro-furan-3-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	430.56	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and Tetrahydro-furan-3-carboxylic acid	431.4
12	4-Acetylamino-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	493.2	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-Acetylamino benzoic acid	494.1
13	2-Methyl-2H-indazole-3-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	490.62	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 2-Methyl-2H-indazole-3-carboxylic acid	491.4

14	2-(4-Chloro-phenyl)- N-trans (4-{2-[4-(4-fluoro-benzoyl)- piperidin-1-yl]-ethyl}- cyclohexyl)- isobutyramide	513.1	Trans-{1-[2-(4-Amino- cyclohexyl)-ethyl]- piperidin-4-yl}-(4- fluoro-phenyl)- methanone (trifluoro acetic acid salt) and 4-chloro-alpha, alpha- dimethylphenyl acetic acid	514.5
15	N-trans-(4-{2-[4-(4- Fluoro-benzoyl)- piperidin-1-yl]-ethyl}- cyclohexyl)-4-(3- methyl-5-oxo-4,5- dihydro-pyrazol-1- yl)-benzamide	532.6	Trans-{1-[2-(4-Amino- cyclohexyl)-ethyl]- piperidin-4-yl}-(4- fluoro-phenyl)- methanone (trifluoro acetic acid salt) and 4-4-(3-methyl-5-oxo- 4,5-dihydro-pyrazol-1- yl)-benzoic acid	533.2
16	6-Chloro-2-methyl- quinoline-3- carboxylic acid trans- (4-{2-[4-(4-fluoro- benzoyl)-piperidin-1- yl]-ethyl}-cyclohexyl)- amide	536.09	Trans-{1-[2-(4-Amino- cyclohexyl)-ethyl]- piperidin-4-yl}-(4- fluoro-phenyl)- methanone (trifluoro acetic acid salt) and 6-Chloro-2-methyl- quinoline-3-carboxylic acid	536.2
17	5-Chloro-1-(3,4- dichloro-benzyl)-6- oxo-1,6-dihydro- pyridine-3-carboxylic acid trans-(4-{2-[4-(4- fluoro-benzoyl)- piperidin-1-yl]-ethyl}- cyclohexyl)-amide	647.02	Trans-{1-[2-(4-Amino- cyclohexyl)-ethyl]- piperidin-4-yl}-(4- fluoro-phenyl)- methanone (trifluoro acetic acid salt) and 5-Chloro-1-(3,4- dichloro-benzyl)-6- oxo-1,6-dihydro- pyridine-3-carboxylic acid	648.1

18	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-methyl-nicotinamide	451.59	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 6-methylnicotinic acid	452.7
19	4-Cyano-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	461.58	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-Cyanobenzoic acid	462.2
20	[1,8]Naphthyridine-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	488.61	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and [1,8]Naphthyridine-4-carboxylic acid trans	489.2
21	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyrazol-1-yl-benzamide	502.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-(1H-pyrazol-1-yl)-benzoic acid	503.1
22	2,4-Dichloro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	505.46	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 2,4-Dichlorobenzoic acid	507.1

23	4-(4-Chloro-benzenesulfonyl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	611.18	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-(4-(4-Chloro-benzenesulfonyl)-benzoic acid	611.8
24	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-trifluoromethoxy-benzamide	520.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-trifluoromethoxy-benzoic acid	521.3
25	3-Ethoxy-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide	432.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 3-Ethoxy-propionic acid	433.3
26	3,3,3-Trifluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide	442.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 3,3,3-Trifluoro-propionic acid	443.1
27	N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(1,1,2,2-tetrafluoro-ethoxy)-	552.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro	553.2

	benzamide		acetic acid salt) and 4-(1,1,2,2-tetrafluoroethoxy)-benzoic acid	
28	N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide	388.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and propionic acid	389.3
29	Cyclohexanecarboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	442.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and cyclohexanecarboxylic acid	443.5
30	Adamantane-1-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	494.7	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and Adamantane-1-carboxylic acid	495.4
30A1	2,2,2-Trifluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	450.9	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and trifluoroacetic acid	453.0
30A2	5-Fluoro-1H-indole-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-	493.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro	494.0

	amide		acetic acid salt) and 5-Fluoro-1H-indole-2-carboxylic acid	
30A3	5-Trifluoromethoxy-1H-indole-2-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	559.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) 5-Trifluoromethoxy-1H-indole-2-carboxylic acid	560
30A4	5-Methoxy-1H-indole-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	505.3	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and 5-Methoxy-1H-indole-2-carboxylic acid	506.0
30A5	2-Cyclopropyl-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	414.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and 2-Cyclopropyl acid	416
30A6	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-butyramide	402.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and butyric acid	403.0
30A7	Thiophene-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-	442.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoro	443.2

	amide		acetic acid salt) and Thiophene-2-carboxylic acid	
30A8	3H-Imidazo[4,5-b]pyridine-6-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	477.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid	478.3
30A9	2-Methyl-cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	414.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and 2-Methyl-cyclopropanecarboxylic acid	415.4
30A10	5-Methanesulfonyl-thiophene-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	520.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and 5-Methanesulfonyl-thiophene-2-carboxylic acid	521.3
30A11	6-Fluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-nicotinamide	455.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and 6-Fluoro nicotinic acid	456.2
30A12	4-Methoxy-	472.6	Trans-{1-[2-(4-Amino-	473.3

	cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide		cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-Methoxy-cyclohexanecarboxylic acid	
30A13	4-Hydroxy-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	458.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) and 4-Hydroxy-cyclohexanecarboxylic acid	459.5
30A14	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-butyramide	432.6	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 3-methoxy-butyric acid (obtained by saponification of the ester)	433.5
30A15	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyridin-3-yl-benzamide	513.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 4-pyridin-3-yl-benzoic acid	514.1
30A16	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyridin-4-yl-benzamide	513.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 4-pyridin-4-yl-benzoic	514.1

			acid	
30A17	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyridin-2-yl-benzamide	513.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-pyridin-2-yl-benzoic acid	514.1
30A18	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(4-methyl-piperazin-1-yl)-benzamide	534.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-(4-methylpiperazino)benzoic acid	535.1
30A19	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-morpholin-4-yl-nicotinamide	522.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-(4-methylpiperazino)benzoic acid	523.7
30A20	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-phthalazin-1-yl-benzamide	564.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-phthalazin-1-yl-benzoic acid	565.0
30A21	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-4-pyridin-2-yl-benzamide	543.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 3-methoxy-4-pyridin-2-yl-benzoic acid	544.0
30A22	Biphenyl-4-carboxylic	512.7	Trans {1-[2-(4-amino-	513.5

	acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide		cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 4-diphenylcarbonic acid	
30A23	3-Methyl-chroman-3-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	506.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 3-methyl-chroman-3-carboxylic acid (prepared as described on WO200386288)	507.3
30A24	2-Morpholin-4-yl-pyrimidine-5-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	523.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 2-Morpholin-4-yl-pyrimidine-5-carboxylic acid	524.2
30A25	6-Morpholin-4-yl-pyridazine-3-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	523.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 6-Morpholin-4-yl-pyridazine-3-carboxylic acid	524.0
30A26	5-Morpholin-4-yl-pyrazine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	523.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 5-Morpholin-4-yl-pyrazine-2-carboxylic acid	524.2

30A27	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-phenoxy-propionamide	480.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 3-phenoxypropionic acid	481.2
30A28	3-Phenyl-propynoic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	460.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and phenylpropionic acid	461.2
30A29	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-hydroxy-2,2-dimethyl-propionamide	432.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 2,2-dimethyl-3-hydroxypropionic acid	433.4
30A30	2-Fluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide	539.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 2-fluoro-4-morpholin-4-yl-benzoic acid (prepared according to Biorganical and Medicinal chemistry letters (2005), 15(5), 1529-1534.	540.1
30A31	Benzo[1,3]dioxole-5-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	480.57	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 2-fluoro-4-morpholin-4-	481.1

			yl-benzoic acid	
30A32	3-Methyl-isoxazole-5-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	441.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 3-Methyl-isoxazole-5-carboxylic acid	442.5
30A33	4-(3,3-Dimethyl-2-oxo-azetidin-1-yl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	533.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-(3,3-Dimethyl-2-oxo-azetidin-1-yl)-benzoic acid	534.2
30A34	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-ylmethyl-benzamide	535.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-(Morpholinomethyl)benzoic acid	536.2
30A35	2-Benzo[d]isoxazol-3-yl-N-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	491.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 2-(1,2-benzisoxazol-3-yl)acetic acid	492.4
30A36	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide	455.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 3-Methyl-5-	456.3

			isoxazoleacetic acid	
30A37	2-(3,5-Dimethoxy-phenyl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	510.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 3, 5-diemthoxyphenylacetic acid	511.5
30A38	2-Benzo[1,3]dioxol-5-yl-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	494.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 3,4-methylenedioxyphenyla cetic acid	495.4
30A39	Trans N-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-isonicotinamide	467.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 2-methoxy-isonicotinic acid	468.4
30A40	4-tert-Butoxy-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	508.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-tert-Butoxy benzoic acid	509.5
30A41	4-Dimethylamino-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	479.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-Dimethylamino benzoic acid	480.3

30A42	4-(1,1-Dioxo-6-thiomorpholin-4-yl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	569.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-(1,1-Dioxo-4-thiazinan-4-yl)benzenecarboxylic acid	570.4
30A43	3-Fluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide	539.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 3-fluoro-4-morpholin-4-yl-benzoic acid	540.1
30A44	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(3-hydroxy-pyrrolidin-1-yl)-benzamide	521.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-(3-hydroxy-pyrrolidin-1-yl)-benzoic acid (prepared according to Biorganic and Medicinal Chemistry Letters (2005), 15(5), 1529)	522.5
30A45	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(4-hydroxy-piperidin-1-yl)-benzamide	535.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-(4-hydroxy-piperidin-1-yl)-benzoic acid (prepared according to Biorganic and Medicinal Chemistry Letters (2005), 15(5), 1529).	536.4

30A46	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-thiomorpholin-4-yl-benzamide	537.8	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-thiomorpholin-4-yl-benzoic acid (prepared according to Biorganic and Medicinal Chemistry Letters (2005), 15(5), 1529)	538.4
30A47	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-piperidin-1-yl-benzamide	519.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-piperidine-1-yl-benzoic acid	520.3
30A48	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-morpholin-4-yl-nicotinamide	522.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-morpholinonicotinic acid	523.7
30A49	2,3-Dihydro-benzo[1,4]dioxine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	494.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 1,4-benzodioxan-2-carboxylic acid	495.3
30A50	(1S,4R)-Bicyclo[2.2.1]heptane-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-	494.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and	495.3

	yl]-ethyl)-cyclohexyl)-amide		(1S,4R)-Bicyclo[2.2.1]heptane-2-carboxylic acid	
30A51	(1R,4R)-7,7-Dimethyl-2-oxo-bicyclo[2.2.1]heptane-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	496.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and (1R,4R)-7,7-Dimethyl-2-oxo-bicyclo[2.2.1]heptane-1-carboxylic acid	497.4
30A52	4-Trifluoromethyl-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	510.62	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-Trifluoromethyl-cyclohexanecarboxylic acid	511.5
30A53	1-Methyl-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	456.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 1-Methyl-cyclohexanecarboxylic acid	457.5
30A54	4-Methyl-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	456.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-Methyl-cyclohexanecarboxylic acid	457.5
30A55	6-Hydroxy-bicyclo[2.2.2]octane-	484.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-	485.4

	2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide		piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 6-Hydroxy-bicyclo[2.2.2]octane-2-carboxylic acid	
30A56	1-Trifluoromethyl-cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	456.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 1-Trifluoromethyl-cyclopropanecarboxylic acid	457.5
30A57	3-Chloro-cyclobutanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	449.01	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 3-Chloro-cyclobutanecarboxylic acid	449.5
30A58	Acetic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexylcarbamoyl)-methyl ester	432.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and acetoxyacetic acid	433.4
30A59	1-Hydroxy-cyclopropanecarboxylic acid (trans-4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	416.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 1-hydroxy-cyclopropanecarboxylic acid	417.4
30A60	Cyclobutanecarboxylic acid trans (4-{2-[4-	414.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-	415.5

	(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-amide		piperidin-4-yl)-(4-fluoro-phenyl)-methanone and Cyclobutanecarboxylic acid	
30A61	4-Hydroxy-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-amide	458.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 4-Hydroxy-cyclohexanecarboxylic acid	459.4
30A62	2,2-Difluoro-cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-amide	436.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 2,2-Difluoro-cyclopropanecarboxylic acid	437.2
30A63	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-2-morpholin-4-yl-benzamide	522.4	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone and 2-morpholino benzoic acid	521.6

Example 30A64

Trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-carbamic acid methyl ester

5

Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (trifluoro acetic acid salt) (30mg, 0.082mmol) was dissolved in 1 ml dichlormethan. The

reaction was cold down to 0°C. Dimethyl pyrocarbonate (10.9mg, 0.082mmol) and triethylamine (8.3mg, 0.082mmol) were added. The reaction mixture was stirred over night at r.t. Aqueous solution of sodium bicarbonate was added until pH 8 and the water phase was extracted with dichloromethane. Chromatographie with dichloromethan/Methanol (1/0 to 8/2) yield the desired compound as a white solid (24mg, 69.1%).

Example 30A65

5-(4-Methyl-piperazin-1-yl)-pyridine-2-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

Step 1: 5-Bromo-pyridine-2-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

The title compound, MS: m/e = 515.9/517.9 (M+H⁺), was prepared according to the procedure described for the synthesis of example 1 from the respective trans-{1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (*example 1, intermediate F*) and 5-bromo-2-carboxy pyridine.

Step 2: 5-(4-Methyl-piperazin-1-yl)-pyridine-2-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

5-Bromo-pyridine-2-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide (80 mg, 0.15 mmol) and 1-methylpiperazine (31 µl, 0.28 mmol) were dissolved in 2 ml dioxane. 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (9 mg, 0.016 mmol), cesium carbonate (76 mg, 0.23 mmol), water (1 µl, 0.078 mmol) and tri(dibenzylideneacetone)dipalladium chloroform complex (8 mg, 0.008 mmol) were added and the reaction mixture was stirred for 16 hrs at 110°C. The reaction mixture was then evaporated and purified by flash chromatography on silica gel (dichloromethane/methanol 100:0 -> 90:10 gradient). The desired product was obtained as a light red solid (33 mg, 40%), MS: m/e = 536.0 (M+H⁺).

Example 30A66

5-Morpholin-4-yl-pyridine-2-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

The title compound, MS: $m/e = 523.2$ ($M+H^+$), was prepared in accordance with the general method of example 30A65, step 2 from 5-bromo-pyridine-2-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide and morpholine.

Example 30A67

5-Phenyl-pyridine-2-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

5-Bromo-pyridine-2-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide (*example 30A66, step 1*) (80 mg, 0.155 mmol) and phenylboronic acid (27 mg, 0.22 mmol) were dissolved under argon in 0.4 ml 2M sodium carbonate and 1.6 ml 1,2-dimethoxyethane. Triphenylphosphine (16 mg, 0.062 mmol) and Pd(II)acetate (7 mg, 0.03 mmol) were added and the mixture stirred at 85°C for 16 hrs. The reaction mixture was extracted with water and two times dichloromethane. The organic extracts were washed with water and brine, dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (dichloromethane/methanol 100:0 -> 90:10 gradient). The desired compound was obtained as a brown solid (36 mg, 45%), MS: $m/e = 514.1$ ($M+H^+$).

20

Example 31

Quinoline-4-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

Intermediate B

25 Trans-(4-Amino-cyclohexyl)-acetic acid ethyl ester

Step 1.

(4-Nitro-phenyl)-acetic acid (0.005 g, 276mmol) was added to a stirred solution of 22.08g of 50% sodium hydroxide solution in 450mL deionized water. The clear yellow solution was transferred into a high-pressure autoclave that it charged with 30g (511 mmol) of

water-wet sponge nickel catalyst. The autoclave was sealed, flushed with nitrogen and then pressurized to 115 bar with hydrogen. The reaction mixture was stirred and heated to 125°C for 48h. At that time the autoclave was cooled, vented and charged under nitrogen with another 30g (511 mmol) of the sponge nickel catalyst. The autoclave was flushed again
5 with nitrogen and then pressurized to 115 bar and the vessel is heated to 130°C while stirring (a maximum pressure of 130 bars is observed). Hydrogenation is continued for 5 days to 130°C. The autoclave is then cooled, vented and flushed with nitrogen and the contents are removed and filtered through filter aid to remove catalyst. After removal of the solvent a crude was obtained. The intermediated is used directly in the next step without
10 purification. MS (m/e): 158.3 (M+H⁺)

step 2

A solution of the Trans-(4-amino-cyclohexyl)-acetic acid obtained (74g, 476mmol) was adjusted to pH 5 with 25% HCl. The mixture was evaporated to dryness and dried under vacuum overnight. The residue was suspended in 146mL of a 6.5N ethanolic HCl solution
15 and 0.6L of ethanol was added to the mixture. After 4 h refluxing, the mixture was cooled, filtered and the filtrate was concentrated to dryness under vacuum. The residue was dissolved in ethanol, treated with ether and cooled overnight in the refrigerator, to give the Trans-(4-Amino-cyclohexyl)-acetic acid ethyl ester hydrochloride (19.7 g, 32% on the two steps) as a white solid which was filtered and dried under vacuum. MS (m/e): 186.1
20 (M+H⁺)

Intermediate G

Step 1

{Trans -4 -[(Quinoline-4-carbonyl)-amino]-cyclohexyl}-acetic acid ethyl ester
hydrochloride salt

A mixture of Trans-(4-Amino-cyclohexyl)-acetic acid ethyl ester hydrochloride (3.63 g, 17 mmol) is solved in dichloromethane (115mL) and quinoline-4-carbonyl chloride hydrochloride is added (4.184 g, 18mmol) followed by the slow addition of triethylamine (11.3mL, 81mmol) at 0°C. The mixture is stirred at room temperature overnight and the salts obtained are removed by filtration and the filtrate is extracted. The organic layer is washed with NaHCO₃ and brine. The organic phases are dried and concentrated to obtain 3.8 g of a crude .After a flash chromatography with heptane/AcOEt 4:1 to AcOEt a solid was obtained that was recrystallized with EtOAc and n-heptane to obtain the title compound as a pink solid (2.72 g, 42% yield). MS (m/e): 341.3 (M+H⁺).

10 Step 2

Trans-{4-[(Quinoline-4-carbonyl)-amino]-cyclohexyl}-acetic acid

4-[(Quinoline-4-carbonyl)-amino]-cyclohexyl}-acetic acid ethyl ester hydrochloride salt (2.7 g, 8 mmol) was reacted with lithium hydroxide monohydrate (3.33g, 79 mmol) in a mixture of water (65mL) and THF (130mL) and the mixture was heated at reflux for 5 hours. A 2/3 of the mixture was evaporated and HCl 37% was added until pH 7. The mixture is then evaporated to dryness and 30 mL of water is added and the suspension is filtered to obtain a solid that was recrystallized on toluene (2.2 g, 88.6% yield). MS (m/e): 313.1 (M+H⁺).

Intermediate H

20 Trans-{4-[(Quinoline-4-carbonyl)-amino]-cyclohexyl}-thioacetic acid S- ethyl ester

2.19 g of Trans-{4-[(Quinoline-4-carbonyl)-amino]-cyclohexyl}-acetic acid (7 mmol) was added in 1300 mL of dichloromethane. Then 1.8 mL of oxalyl chloride is added (21 mmol). The suspension was heated to reflux for 3 hours and then the cloudy mixture is concentrated under vacuum. The residue is taken up in 500 mL of dichloromethane as a suspension and (1.28 g, 21 mmol) sodium ethylthiolate freshly prepared from 1.45 mL of ethanethiol and 12.07 mL of Butyl lithium (1.6 M in toluene) at 0°C and by stirring in dimethoxyethane (20mL) for 1 h at room temperature. The reaction mixture was stirred overnight. NaHCO₃ was added and the organic phase was extracted three times with dichloromethane. The organic phases were dried and concentrated and the residue was chromatographed with heptane/AcOEt 1:1 to AcOEt to yield the title compound as a solid (1.97 g, 78.9% yield). MS (m/e): 357.3 (M+H⁺).

Intermediate I

Quinoline-4-carboxylic acid trans-[4-(2-oxo-ethyl)-cyclohexyl]-amide

Trans-{4-[(Quinoline-4-carbonyl)-amino]-cyclohexyl}-thioacetic acid S-ethyl ester (1.87g, 5 mmol) was solved in acetone / methylene chloride (40/40 mL), 0.8g of molecular sieves were added to the mixture and the solution was stirred for 0.5h. Then 0.558g (1mmol) of palladium on active charcoal 10% was added followed by 1.25 mL (8 mmol) of triethylsilane. The reaction was stirred for 1.5h at room temperature and additional 0.558g (1 mmol) of palladium on active charcoal 10% and 1.25 mL (8 mmol) of triethyl-silane were added and the stirring was continued for another hour. The mixture was filtrated through celite and the mother liquid was concentrated to obtain after chromatography using heptane/AcOEt 1:1 to AcOEt 1.1 (37.1 mmol, 70.8 % yield) of the final compound. MS (m/e): 297.3 (M+H⁺)

Quinoline-4- carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

4-(4-fluorobenzoyl) piperidine (trifluoro-acetic acid salt) (0.020g, 0.062 mmol) was solved in 1,2-dichloromethane (0.300 mL) and Quinoline-4-carboxylic acid trans-[4-(2-oxo-ethyl)-cyclohexyl]-amide (0.020 g, 0.067mmol) was added. Methanol (0.200 mL) was added to the mixture and it was stirred overnight. Sodium triacetoxyborohydride (0.024, 0.11 mmol) was added to the clear solution that was stirred 10 hours at room temperature. The mixture was concentrated to dryness and the residue was taken up on methanol and purified with preparative HPLC on reversed phase eluting with acetonitrile/water. The combined producted fractions were evaporated under reduced pressure to yield 0.03 g of a white solid (0.06 mmol, 99%). MS (m/e): 488.3 (M+H⁺)

According to the procedure described for the synthesis of example 31 further derivatives have been synthesized from the respective Quinoline-4-carboxylic acid trans-[4-(2-oxo-ethyl)-cyclohexyl]-amide and the corresponding phenyl or heteroaryl piperidin-4-yl-methanone (commercially available, obtained by methods known on the art or by methods described on this patent).

Ex. No	Systematic name	MW	Starting materials	MW found (M+H)+
31	Quinoline-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	487.6	Quinoline-4-carboxylic acid trans-[4-(2-oxo-ethyl)-cyclohexyl]-amide and 4-(4-fluorobenzoyl)piperidine (trifluoro-acetic acid salt)	488.3
32	Quinoline-4-carboxylic acid trans-(4-{2-[4-(4-methoxy-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	499.6	Quinoline-4-carboxylic acid trans-[4-(2-oxo-ethyl)-cyclohexyl]-amide and (4-methoxyphenyl)(4-piperidyl)methanone hydrochloride	500.3
33	Quinoline-4-carboxylic acid trans-{4-[2-(4-benzoyl-4-hydroxypiperidin-1-yl)-ethyl]-cyclohexyl}-amide	485.6	Quinoline-4-carboxylic acid trans-[4-(2-oxo-ethyl)-cyclohexyl]-amide and 4-hydroxy-4-piperidyl phenyl	486.4

			ketone hydrochloride	
34	Quinoline-4-carboxylic acid trans-{4-[2-(4-benzoyl-4-fluoro-piperidin-1-yl)-ethyl]-cyclohexyl}-amide	487.6	Quinoline-4-carboxylic acid trans-[4-(2-oxo-ethyl)-cyclohexyl]-amide and (4-Fluoro-piperidin-4-yl)-phenyl-methanone (trifluoro-acetic acid salt)	488.4
35	Quinoline-4-carboxylic acid trans-(4-{2-[4-(3,4-dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	538.52	Quinoline-4-carboxylic acid trans-[4-(2-oxo-ethyl)-cyclohexyl]-amide and (3,4-Dichloro-phenyl)-piperidin-4-yl-methanone	538.4

Example 36N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone
 5 (intermediate F, example 1) (0.03 g, 0.09 mmol) is suspended in dichloromethane (0.300mL) and triethylamine is added (0.01 mL, 0.094mmol) followed by acetylchloride (0.010 mL, 0.094 mL) and the mixture was stirred for 2 hours at room temperature until
 TLC indicated the end of the reaction. The solvent was removed and DMF (0.8 mL) was
 added and the solution was purified with preparative HPLC on reversed phase eluting with
 10 acetonitrile/water (0.05% Et₃N). The combined producted fractions were evaporated under reduced pressure to yield 0.008 g of a off-white solid (0.02 mmol, 22.2%). MS (m/e): 375.3 (M+H⁺)

According to the procedure described for the synthesis of example 36 further derivatives have been synthesized from the Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-

(4-fluoro-phenyl)-methanone and the corresponding acyl chlorides. They comprise examples 36 and 37.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H)+
36	N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	374.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and acetylchloride	375.2
37	Morpholine-4-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	445.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-morpholinylcarbonyl chloride	446.3

5 Example 38

Trans-1-(2,4-Dichloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea

Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (*example 1, intermediate F*) (0.03 g, 0.09 mmol) was suspended in acetonitrile (0.300mL) and 2,4-Dichlorophenyl isocyanate was added (0.019 g, 0.1 mmol) and the mixture was stirred for 2 hours at room temperature until TLC indicated the end of the reaction. The solvent was removed and the crude was purified with chromatography eluting with dichloromethane/methanol (1/0 to 9/1). The combined product fractions were evaporated

under reduced pressure to yield 0.001 g of a white solid (0.019 mmol, 21 %). MS (m/e): 375.3 (M+H⁺)

According to the procedure described for the synthesis of example 38 further derivatives have been synthesized from the respective Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and the corresponding isocyanate.
5 They comprise examples 38 to 41.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
38	Trans-1-(2,4-Dichloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea	520.4	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 2,4-Dichlorophenyl isocyanate	520.5
39	Trans-1-(4-Chloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea	520.4	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 4-Chlorophenyl isocyanate	520.5
40	Trans-1-(4-Ethoxy-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea	486.03	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and	486.5

			4-Ethoxyphenyl isocyanate	
41	Trans-1-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-p-tolyl-urea	465.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and p-tolyl isocyanate	466.1

Example 42Trans-1-(4-Chloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-1-methyl-urea

- 5 Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (*example 1, intermediate F*) (0.05 g, 0.1 mmol) is suspended in acetonitrile (1 mL) and (4-chloro-phenyl) methyl carbamic acid 4-nitro-phenyl ester (prepared from 4-chloro-N-methylaniline and 4-nitrophenyl chloroformate with triethylamine in dichloromethane stirring at room temperature) was added (0.034g, 0.1mmol) followed by N,N-diisopropyl
- 10 ethyl amine (0.04mL, 0.2 mmol) and the mixture was stirred for 24 hours at 75°C until TLC indicated the end of the reaction. The solvent was removed and crude was purified with chromatography eluting with dichloromethane/methanol (1/0 to 9/1). The combined product fractions were evaporated under reduced pressure to yield 0.02 g of a white solid (0.04 mmol, 40%). MS (m/e): 501.2 (M+H⁺).

15

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
42	Trans-1-(4-Chloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-1-methyl-	500.1	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-	501.2

	urea		phenyl)- methanone and (4- chloro- phenyl) methyl carbamic acid 4-nitro- phenyl ester	
--	------	--	---	--

Example 42A12,3-Dihydro-indole-1-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

- 5 Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (*example 1, intermediate F*) (80 mg, 0.24 mmol) was dissolved in 1.5 ml dichloromethane and N-ethyldiisopropylamine (0.33 ml, 1.93 mmol) was added. Triphosgene (79 mg, 0.27 mmol) was added carefully and the solution stirred for 30 minutes at room temperature. Indoline (32 mg, 0.27 mmol) was added and stirred for 30 minutes at room temperature.
- 10 The reaction mixture was extracted with sat. NaHCO₃-solution and dichloromethane. The organic extracts were washed with brine, dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (dichloromethane/methanol 100:0 -> 90:10 gradient). The desired compound was obtained as a white solid (51 mg, 44%), MS: m/e = 478.2 (M+H⁺).

15

According to the procedure described for the synthesis of example 42A1 further derivatives have been synthesized from the respective Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone (*example 1, intermediate F*) and the corresponding amine. They comprise examples 42A2 to 42A7.

20

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
-----------	-----------------	----	--------------------	-----------------------------------

42A2	6-Trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	545.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 6-(trifluoromethyl)indoline	546.2
42A3	1,3-Dihydro-isoindole-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	477.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and isoindoline	478.2
42A4	3,4-Dihydro-1H-isoquinoline-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	491.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and 1,2,3,4-tetrahydroisoquinoline	492.1
42A5	3-Phenoxy-pyrrolidine-1-carboxylic acid trans (4-{2-[4-	521.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-	522.2

	(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl]-cyclohexyl)-amide		methanone and (RS)-3-phenoxy-pyrrolidine	
42A6	1,1-Dioxo-thiomorpholine-4-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl]-cyclohexyl)-amide	493.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and (1,1-Dioxo-thiomorpholine-4-carboxylic acid	494.4
42A7	Trans- 3-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl]-cyclohexyl)-1,1-dimethyl-urea	403.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and dimethyl amine	404.4

Example 43

N-{(Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide

Intermediate K

Trans-2-[tert-Butoxycarbonylamino-(toluene-4-sulfonyl)-methyl]-cyclopropanecarboxylic acid ethyl ester

2-Formyl-cyclopropanecarboxylic acid ethyl ester (88-90% trans isomer) (2.9g, 20.4 mmol) is solved in methanol and 2.4 g (20.49 mmol) of tert-butylcarbamate was added followed by sodium p-toluensulfinate in water (40mL). After stirring at room temperature 5 mL (132.5 mmol) of formic acid was added and the mixture is stirred for 70 minutes until the

product precipitated. The solid was filtrated and washed with water and heptane and dried under high vacuum to obtain 3.6g. (44.5% yield) of the title compound (only the trans isomer) as a white solid. MS (m/e): 384.5 (M+H⁺)

Intermediate L

5 Trans-2-(tert-Butoxycarbonylamino-methyl)-cyclopropanecarboxylic acid ethyl ester

Sodium Borohydride (2.3 g, 58.55 mol) was suspended in tetrahydrofuran (150mL) and 4mL of water was added. (13.3 g, 33.46 mmol) of trans-2-[tert-Butoxycarbonylamino-(toluene-4-sulfonyl)-methyl]-cyclopropanecarboxylic acid ethyl ester was added portionwise (0.8 g portions) and the temperature was kept to 18-30°C. After 1.5 h water
10 (4mL) and 0.4g (10.15mmol) of sodium borohydride were added again. The resulting mixture was quenched with ammonium chloride 2M (300mL) and 100 mL of 1M K₂CO₃ and stirring was continued for 0.5h. The organic layer was separated and the aqueous phase was extracted with ethyl acetate (300mL) and the combined organic layers were dried over MgSO₄ and concentrated to dryness under vacuum and purified with column
15 chromatography on silica with heptane/AcOEt (9/1) to obtain 7.5 g (92.1% yield) of the title compound.as a white solid. MS (m/e): 244.1 (M+H⁺)

Intermediate M

Trans-(2-Formyl-cyclopropylmethyl)-carbamic acid tert-butyl ester

To a solution of Trans-2-(tert-Butoxycarbonylamino-methyl)-cyclopropanecarboxylic
20 acid ethyl ester_(0.320 g, 1.3 mmol), in toluene (5 mL) at -78°C a 1.2M solution of DIBAL-H (1.86 mL, 2.2 mmol) in toluene was added. The mixture was stirred at -78°C until TLC after 0.5h indicated completion of the reaction. A saturated solution of sodium tartrate was added and the water was extracted three times with dichloromethane. The combined
organic layers were washed with water and brine, dried over magnesium sulfate, filtered
25 and evaporated. The crude product was used without purification on the next step. MS (m/e): 200.3 (M+H⁺)

Intermediate N

{Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-carbamic acid tert-butyl ester

30 A mixture of 4-(4-fluorobenzoyl) piperidine (0.300 g, 1.2 mmol), Trans-(2-Formyl-cyclopropylmethyl)-carbamic acid tert-butyl ester (0.294 g, 1.2 mmol), in 1, 2

dichloroethane (2mL) was stirred for 4 h at room temperature and sodium triacetoxyborohydride (0.470 g, 2.2 mmol) was added and the resulting solution was stirred for 12 hours until the TLC indicated completion of the reaction. The mixture was filtrated and concentrated to dryness and purified with column chromatography on silica gel using
5 CH_2Cl_2 - CH_2Cl_2 / MeOH (1-9:1). The product fractions were concentrated to give 0.288 g (0.74 mmol, 60 % yield) of a white solid. MS (m/e): 391.3 ($\text{M}+\text{H}^+$).

[1-(Trans-2-Aminomethyl-cyclopropylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt

10 0.288 g (0.74 mmol) of {trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-carbamic acid tert-butyl ester is solved in dichloromethane (5 mL) and trifluoroacetic acid is added at 0°C (0.757 mL, 6.6 mmol) and the mixture is stirred at room temperature overnight. NaHCO_3 is slowly added until pH 9 and the mixture
15 extracted with 3 times with dichloromethane and ethyl acetate. The solvent was evaporated to yield 0.308 g (0.76 mmol, 100%) of a white solid that was used without purification on the next steps. MS (m/e): 291.2 ($\text{M}+\text{H}^+$).

N-[(Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide

20 3-(5-methyl-1,2,4-oxadiazol-3-yl) benzoic acid (0.015g, 0.074 mmol), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate (0.024 g, 0.074 mmol) and (0.04 mL, 0.224 mmol) of N- ethyldiisopropylamine were stirred in 0.3 mL of DMF for 0.5h at room temperature and [1-(Trans-2-Aminomethyl-cyclopropylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt (0.030g, 0.074 mmol) was added. The
25 mixture was stirred for 12 hours at room temperature. The mixture was concentrated to dryness and the residue was purified with chromatography using dichloromethane and methanol (9:1) . The combined producted fractions were evaporated under reduced pressure to yield 0.02 g of a light brown solid (0.04 mmol, 56.6%). MS (m/e): 477.0 ($\text{M}+\text{H}^+$).

30 According to the procedure described for the synthesis of example 43 further amide derivates were synthesized from [1-(Trans-2-Aminomethyl-cyclopropylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone (trifluoroacetic acid salt) and the respective commercially available acid. The purification was performed with preparative HPLC on

reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective amides which comprise examples 43 to example 45.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H)+
43	N-{Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide	476.5	[1-(Trans-2-Aminomethyl-cyclopropylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 3-(5-methyl-1,2,4-oxadiazol-3-yl) benzoic acid	477.0
44	2-(4-Chloro-phenyl)-N-{ Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-isobutyramide	471.02	[1-(Trans-2-Aminomethyl-cyclopropylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-chloro-alpha, alpha-dimethylphenyl acetic acid	471.3
45	4-Chloro-N-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-benzamide	428.9	[1-(Trans-2-Aminomethyl-cyclopropylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-	429.5

			Chlorobenzoic acid	
--	--	--	--------------------	--

Example 461-(4-Chloro-phenyl)-3-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-urea

- 5 The title compound was synthesized from [1-(Trans-2-Aminomethyl-cyclopropylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone, trifluoroacetic acid salt and 4-chlorophenyl isocyanate in acetonitrile according to the procedure described for example 21. MS (m/e): 444.0 (M+H⁺)

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
46	1-(4-Chloro-phenyl)-3-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-urea	443.95	[1-(Trans-2-Aminomethyl-cyclopropylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone, trifluoroacetic acid salt and 4-chlorophenyl isocyanate	444.0

10

Example 472-(4-Chloro-phenyl)-N-{trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-isobutyramideIntermediate P

- 15 Trans-2-Hydroxymethyl-cyclobutanecarboxylic acid methyl ester

Trans-Cyclobutan-1,2-carboxylic acid dimethylester (24.6 g, 142.9 mmol), was solved in 310mL of methanol and sodium borohydride was added.(12.7 g, 322 mmol) in 5 portions each 40 minutes keeping the temperature at 0°C. After the last addition the mixture was stirred for 2 hours. 2M aqueous ammonium chloride (500mL) and sulfuric acid 2M (76 mL) were added until pH 7. The aqueous phase was extracted 3 times with 150 mL of dichloromethane and the organic layers were purified with column chromatography using a mixture of dichloromethane and TBME (4 +1) to obtain 15.3 g of the title compound (106 mmol, 74% yield) as a colourless liquid. MS (m/e): 167.2 (M+Na⁺)

Intermediate Q

10 Trans-2-Formyl-cyclobutanecarboxylic acid methyl ester

At -78°C, oxalyl Chloride (9.2 mL, 106.5 mmol) was solved in dichloromethane (250mL) and (15.5 mL, 218 mmol) of dimethylsulfoxide in 20 mL of dichloromethane was added. After 15 minutes of stirring at -78°C, Trans-2-Hydroxymethyl-cyclobutanecarboxylic acid methyl ester (14g, 95.17 mmol) was added in 78 mL of dichloromethane and 10 minutes later triethylamine (67 mL, 479 mmol) was added and the mixture was stirred for 2 h at -78°C. 150 mL of dichloromethane added and 200 mL of water were added and the aqueous phase was extracted with 200 mL of dichloromethane and the combined organic phases were purified with column chromatography on silica using n-heptane/ AcOEt (4+1) to yield 11.1g, (78 mmol, 82% yield) of the title compound as a colourless liquid. MS (m/e): 165.2 (M+ Na⁺)

Intermediate R

Trans-2-[tert-Butoxycarbonylamino-(toluene-4-sulfonyl)-methyl]-cyclobutanecarboxylic acid methyl ester

According to the synthesis of Trans-2-[tert-Butoxycarbonylamino-(toluene-4-sulfonyl)-methyl]-cyclopropanecarboxylic acid ethyl ester (intermediate K, example 43) the title compound was prepared from Trans-2-Formyl-cyclobutanecarboxylic acid methyl ester, (11.1 g, 73.4 mmol), tert-butylcarbamate (12.4g, 105.8 mmol), sodium p-toluenesulfinate in water (19.1g, 104.6 mmol) and formic acid (24 mL, 636.1 mol) and 29.17 g, (73.4 mmol, 84.3% yield) was obtained. MS (m/e): 384.5 (M+H⁺)

30 Intermediate S

Trans-(2-Hydroxymethyl-cyclobutylmethyl)-carbamic acid tert-butyl ester

Step 1

Trans-2-(tert-Butoxycarbonylamino-methyl)-cyclobutanecarboxylic acid methyl ester

- According to the synthesis of Trans-2-(tert-Butoxycarbonylamino-methyl)-
5 cyclopropanecarboxylic acid ethyl ester (intermediate L, example 43), the title compound was prepared from Trans-2-[tert-Butoxycarbonylamino-(toluene-4-sulfonyl)-methyl]-cyclobutanecarboxylic acid methyl ester (17.7 g, 44.53 mmol), sodium borohydride (3.3g, 83.74mmol) and 8.2 g, (33.7 mmol, 73.4%yield) was obtained. MS (m/e): 244.0 (M+H⁺).

Step 2

10 Trans-(2-Hydroxymethyl-cyclobutylmethyl)-carbamic acid tert-butyl ester

- To a solution of Trans-2-(tert-Butoxycarbonylamino-methyl)-cyclobutanecarboxylic acid methyl ester (4.1 g, 16.8 mmol) in methanol (20 mL) at 0°C, sodium Borohydride (1.3 g , 33.6 mmol) was added portionwise. The mixture was stirred 4 h until TLC after TLC indicated completion of the reaction. A saturated solution of ammonium chloride was
15 added, the methanol was removed under vacuum and the water was extracted three times with dichloromethane. The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered, evaporated and purified with column chromatography on silica gel using n-Heptane-EtOAc (1:1). The product fractions were concentrated to give 2.8 g (16.8 mmol, 80 % yield) of the title compound as a white solid.
20 MS (m/e): 216.3 (M+H⁺)

Intermediate TMethanesulfonic acid trans-2-(tert-butoxycarbonylamino-methyl)-cyclobutylmethyl ester

- At 0°C trans-(2-Hydroxymethyl-cyclobutylmethyl)-carbamic acid tert-butyl ester (1g, 4.6 mmol), was solved in 10mL of dichloromethane and methanosulfonylchloride (0.585 g,
25 4.6mmol) was added followed by (1.19 mL, 7mmol) of N,N-diisopropylethylamine . The mixture was stirred 1h at 0°C and and aqueous solution of ammonium chloride was added and the aqueous phase was extracted with 200 mL of dichloromethane and the combined organic phases were purified with column chromatography on silica using n-heptane/ AcOEt (1/1) to yield 1.27 g, (4.4 mmol, 94.5% yield) of the title compound as a
30 light yellow liquid. MS (m/e): 294.2 (M+H⁺).

Intermediate N

Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-carbamic acid tert-butyl ester

A mixture of 4-(4-fluorobenzoyl) piperidine (0.500 g, 2.0 mmol), methanesulfonic acid trans-2-(tert-butoxycarbonylamino-methyl)-cyclobutylmethyl ester (0.662 g, 2.2 mmol),
5 and triethylamine (0.71 mL, 5 mol) in acetonitrile (4mL) was stirred for 12 h at 80°C. The mixture was concentrated to dryness, extracted with 10mL dichloromethane and purified with column chromatography on silica using dichloromethane-methanol (9:1). The product fractions were concentrated to give 0.759 g (1.9 mmol, 91.5 % yield) of a light brown solid. MS (m/e): 405.5 (M+H⁺).

10 [1-(Trans-2-Aminomethyl-cyclobutylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt

According to the synthesis of [1-(Trans-2-Aminomethyl-cyclopropylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt (from example 43), the title compound was prepared from Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-
15 cyclobutylmethyl}-carbamic acid tert-butyl ester and trifluoroacetic acid. MS (m/e): 291.2 (M+H⁺).

Example 47

20 N-{(Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide

According to the procedure described for the synthesis of N-{(trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide (example 43), the title compound was prepared from [1-(trans-2-Aminomethyl-cyclobutylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-
25 acetic acid salt and 3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzoic acid. (m/e): 491.2(M+H⁺).

Further amide derivatives were synthesized from [1-(trans-2-Aminomethyl-cyclobutylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate, N-ethyl-diisopropylamine and the respective commercially available acid listed in table C. The
30 purification was performed with preparative HPLC on reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective amides which comprise examples 47 to example 48.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
47	N-{Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide	490.5	[1-(trans-2-Aminomethyl-cyclobutylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzoic acid	491.2
48	2-(4-Chloro-phenyl)-N-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-isobutyramide	485.04	[1-(trans-2-Aminomethyl-cyclobutylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-chloro-alpha, alpha-dimethylphenyl acetic acid	485.4

Example 49

5 1-(4-Chloro-phenyl)-3-{trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-urea

The title compound was synthesized from 1-(Trans-2-Aminomethyl-cyclobutylmethyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-chlorophenyl isocyanate in acetonitrile according to the procedure described for example 38. MS (m/e): 458.1 (M+H⁺)

Ex. No	Systematic name	MW	Starting materials	MW found (M+H)+
49	1-(4-Chloro-phenyl)-3-{trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-urea	457.9	1-(Trans-2-Aminomethyl-cyclobutylmethyl)-piperidin-4-yl)-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-Chlorophenyl isocyanate	458.1

Example 50

N-trans-(4-[2-[4-Fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl]-cyclohexyl)-3-methoxy-propionamide

Intermediate AA4-(4-Fluoro-benzoyl)-piperidine-1-carboxylic acid tert-butyl ester

4-(4-fluorobenzoyl)piperidine hydrochloride (1.5g, 6.16mmol) was suspended in acetonitrile (30mL) and triethylamine (0.940mL, 6.8mmol), dimethylaminopyridine (0.150g, 1.2mmol) and Di-tert.-butyl-dicarbonate (1.6g, 7.4mmol) were added at 0°C and the mixture was stirred at room temperature for 3h. The solvent was evaporated and aqueous 1M HCl is added (20mL) and the water was extracted with ethyl acetate (100mL). and purified with column chromatography on silica using n-heptane-EtOAc (1 :1). The product fractions were concentrated to give 1.87 g (6.08mmol, 99 % yield) of a white solid.

MS (m/e): 307.3 (M+H⁺).

Intermediate AB4-Fluoro-4-(4-fluoro-benzoyl)-piperidine-1-carboxylic acid tert-butyl ester

4-(4-Fluoro-benzoyl)-piperidine-1-carboxylic acid tert-butyl ester in 0.5 mL of DMF was added to a solution at 0°C containing 0.5 mL of tBuOH, (0.109 mg, 0.651 mmol) tBuOK and 2mL of DMF. After 20 min stirring at 0°C, N-Fluorobenzenesulfonimide (0.246 g, 0.781 mmol) was added portionwise. The reaction was stirred at 0°C during 45 min. and
5 (0.55 g, 0.33mmol) of tBuOK were added at 0°C and 10 min later (0.123 g, 0.390 mmol) of N-Fluorobenzenesulfonimide. Each 0.5h two more additions of (0.55 g, 0.33mmol) tBuOK and (0.123 g, 0.390mmol) N-Fluorobenzenesulfonimide were repited. 1h later of the last addition the reaction was quenched with 4 mL of water and the DMF was removed under vacuum. The water was extracted with ethyl acetate and the combined organic
10 phases were purified with column chromatography on silica using n-heptane-EtOAc (3 :1). The product fractions were concentrated to give 0.122 g (0.375 mmol, 58 % yield) of a yellow oil. MS (m/e): 326.1 (M+H⁺).

Intermediate D

4-Fluoro-4-(4-fluoro-benzoyl)-piperidine

15 4-Fluoro-4-(4-fluoro-benzoyl)-piperidine-1-carboxylic acid tert-butyl ester (0.122g, 0.375 mmol) was solved in dichloromethane (2 mL) and trifluoroacetic acid (0.258mL, 3.37mmol) was added at 0°C. Aqueous NaHCO₃ is slowly added until pH 9 and the mixture extracted with 3 times with dichloromethane and ethyl acetate. The solvent was evaporated to yield g (0. mmol, 100%) of a white solid that was used without purification
20 on the next steps. MS (m/e): 226.1 (M+H⁺).

Intermediate E

Trans-4-{2-[4-Fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester

The title compound was prepared from 4-Fluoro-4-(4-fluoro-benzoyl)-piperidine and
25 Trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester according to the procedure described for the synthesis of Trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester (intermediate E, example 1) in 1,2 dichloroethane using triacetoxyborohydride . MS (m/e): 451.1 (M+H⁺).

Intermediate F

30 Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-fluoro-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt

The title compound was prepared from Trans-4-(4-{2-[4-Fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester and trifluoroacetic acid according to the procedure described for the synthesis of trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoroacetic acid salt (intermediate F, example 1) . MS (m/e): 351.3 (M+H⁺).

N-trans-(4-{2-[4-Fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide

According to the procedure described for the synthesis of 4-Chloro-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide (example 1) the title compound was synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-fluoro-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt , 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate, N-ethyldiisopropylamine and 3-methoxy-propionic acid. MS (m/e): 437.0 (M+H⁺).

Further amide derivates were synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-fluoro-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate, N-ethyldiisopropylamine and the respective commercially available acid listed in table D. The purification was performed with preparative HPLC on reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective amides which comprise example 50 to example 53 .

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
50	N-trans (4-{2-[4-Fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide	436.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-fluoro-piperidin-4-yl}-(4-fluoro-phenyl)-	437.0

			methanone; trifluoro-acetic acid salt and 3-methoxy- propionic acid	
51	4-Ethoxy-N-trans (4- {2-[4-fluoro-4-(4- fluoro-benzoyl)- piperidin-1-yl]-ethyl}- cyclohexyl)-benzamide	498.6	Trans-{1-[2-(4- Amino- cyclohexyl)- ethyl]-4-fluoro- piperidin-4-yl}- (4-fluoro- phenyl)- methanone; trifluoro-acetic acid salt and 4- Ethoxybenzoic acid	499.0
52	Tetrahydro-furan-3- carboxylic acid trans- (4-{2-[4-fluoro-4-(4- fluoro-benzoyl)- piperidin-1-yl]-ethyl}- cyclohexyl)-amide	448.5	Trans-{1-[2-(4- Amino- cyclohexyl)- ethyl]-4-fluoro- piperidin-4-yl}- (4-fluoro- phenyl)- methanone; trifluoro-acetic acid salt and Tetrahydro- furan-3- carboxylic acid	449.0
53	N-trans (4-{2-[4- Fluoro-4-(4-fluoro- benzoyl)-piperidin-1- yl]-ethyl}-cyclohexyl)- acetamide	392.4	Trans-{1-[2-(4- Amino- cyclohexyl)- ethyl]-4-fluoro- piperidin-4-yl}- (4-fluoro- phenyl)- methanone; trifluoro-acetic	393.2

			acid salt and acetic acid	
--	--	--	------------------------------	--

Example 541-(4-Chloro-phenyl)-3-(4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea

- 5 The title compound was synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-fluoro-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt 4-chlorophenyl isocyanate in acetonitrile according to the procedure described for example 38. MS (m/e): 504.3 (M⁺).

- According to the procedure described for the synthesis of example 54, further urea
 10 derivatives were synthesized from {1-[2-(4-Amino-cyclohexyl)-ethyl]-4-fluoro-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and the respective commercially available isocyanate. The purification was performed with preparative HPLC on reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective ureas which
 15 comprise examples 54 and example 55.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
54	1-(4-Chloro-phenyl)-3-trans (4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea	504.0	{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-fluoro-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-chlorophenyl	504.3

			isocyanate	
55	1-(4-Ethoxy-phenyl)-3-trans (4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea	513.6	{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-fluoro-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-Ethoxyphenyl isocyanate	514.5

Example 56

Quinoline-4-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-4-hydroxy-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

5 Intermediate W

(1-Benzyl-piperidin-4-yl)-(4-fluoro-phenyl)-methanone

(3g, 12.3mmol) of 4-(4-fluorobenzoyl) piperidine hydrochloride was suspended in acetonitrile (60mL) and triethylamine (4.29mL, 31mmol), benzylbromide (1.61mL, 14mmol) and sodium iodide (2.8g, 18 mol) were added. The mixture was stirred at 80°C overnight and after cooling the mixture was filtrated, water was added and the aqueous phase was extracted with 100 mL of dichloromethane. The combined organic phases were dried with magnesium sulfate, filtrated concentrated and purified with column chromatography on silica using dichloromethane/ Methanol (95/0.5) to yield 3.6 g, (12 mmol, 99% yield) of the title compound as a brown solid. MS (m/e): 298.4 (M+H⁺).

15 Intermediate X

(1-Benzyl-4-bromo-piperidin-4-yl)-(4-fluoro-phenyl)-methanone

(1-Benzyl-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (2g, 6.73 mmol) is solved in 500 mL of chloroform, bromo is added (2.14g, 13.4mmol) and the mixture is refluxed for 1h and let to stir overnight. When it is cool the mixture is filtrated to obtain 1.4g of the title compound as a white solid (3.83 mol, 3.8mmol). MS (m/e): 376.1 (M^+).

5 Intermediate Y

6-Benzyl-2-(4-fluoro-phenyl)-2-methoxy-1-oxa-6-aza-spiro[2.5]octane

(1-Benzyl-4-bromo-piperidin-4-yl)-(4-fluoro-phenyl)-methanone (1g, 2.66mmol) is solved in methanol (11 mL), sodium (0.300g, 13.04mmol) was added and the mixture was refluxed for 2h. Water was added, the methanol was concentrated under vacuum and the
10 aqueous phase was extracted with ethyl acetate (50mL). The combined organic phases were dried with magnesium sulfate, filtrated and concentrated to yield 0.644 g, (2 mmol, 75% yield) of the title compound as a yellow oil that was used without purification on the next step. MS (m/e): 328.4 ($M+H^+$).

Intermediate Z

15 (1-Benzyl-4-hydroxy-piperidin-4-yl)-(4-fluoro-phenyl)-methanone

6-Benzyl-2-(4-fluoro-phenyl)-2-methoxy-1-oxa-6-aza-spiro[2.5]octane (0.600g, 1.83mmol) was solved in ether (6 mL), 0.6 mL of aqueous HCl was added (37%) and the reaction mixture was stirred at room temperature. After 0.5h the reaction was finished and water was added and the product precipitate. The mixture was filtrated and the solid was
20 recrystallized ethanol/ether to yield the title compound as a white solid (0.550g, 1.76mmol, 96%). MS (m/e): 314.0 ($M+H^+$).

Intermediate D

(4-Fluoro-phenyl)-(4-hydroxy-piperidin-4-yl)-methanone

(0.550g, 1.76 mmol) of (1-Benzyl-4-hydroxy-piperidin-4-yl)-(4-fluoro-phenyl)-
25 methanone was hydrogenated in 4mL of ethyl acetate and 2 mL of methanol using 0.065g, (0.61mmol) of Palladium on charcoal to yield 0.392 g of the title compound (1.76mmol, 100% yield) as a off-white solid after filtration of the catalyst and removal of the solvent under vacuum. MS (m/e): 314.0 ($M+H^+$).

Intermediate E

(4-{2-[4-(4-Fluoro-benzoyl)-4-hydroxy-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester

The title compound was prepared from ((4-Fluoro-phenyl)-(4-hydroxy-piperidin-4-yl)-methanone and trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester

- 5 according to the procedure described for the synthesis of (4-{2-Trans-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester (intermediate E, example 1) in 1,2 dichloroethane using triacetoxyborohydride . MS (m/e): 451.1 (M+H⁺).

Intermediate F

- 10 Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-hydroxy-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt

The title compound was prepared from (4-{2-[4-(4-Fluoro-benzoyl)-4-hydroxy-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester and trifluoroacetic acid according to the procedure described for the synthesis of trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoroacetic acid salt (intermediate F,

- 15 example 1) . MS (m/e): 351.3 (M+H⁺).

Quinoline-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-4-hydroxy-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

- 20 According to the procedure described for the synthesis of N-Trans-Chloro-N-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide (example 1) the title compound was synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-hydroxy-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and Quinoline-4-carboxylic acid using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate, N-ethyl-diisopropylamine in DMF. MS (m/e): 504.2 (M+H⁺).

- 25 Further amide derivatives were synthesized from {1-[2-(4-Amino-cyclohexyl)-ethyl]-4-hydroxy-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and the respective commercially available acid. The purification was performed with preparative HPLC on reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective amides which comprise examples 56 to example 57 .

30

Ex.	Systematic name	MW	Starting	MW
-----	-----------------	----	----------	----

No			materials	found (M+H)+
56	Quinoline-4-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-4-hydroxy-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	503.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-hydroxy-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and Quinoline-4-carboxylic acid	504.2
57	N-trans (4-{2-[4-(4-Fluoro-benzoyl)-4-hydroxy-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide	534.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-4-hydroxy-piperidin-4-yl}-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzoic acid	535.2

Example 57A1

Trans N-(4-{2-[4-(4-Fluoro-benzoyl)-4-methyl-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

5 Intermediate D

(4-Fluoro-phenyl)-(4-methyl-piperidin-4-yl)-methanone

step 1

N-boc-4-methyl-4-piperidinecarboxylic acid (4 g, 16 mol), 4-Fluorobenzeneboronic acid (2.7g, 20 mol), Pivalic anhydride (4.6g, 25mmol), Pd(OAc)₂ (0.111g, 0.4mol), 1,1'-Bis(diphenylphosphino)ferrocene (0.319g, 0.1mol) and (0.7 mL, 41 mmol) of water are mixed together in 20 mL of tetrahydrofuran and the mixture heated at 60°C overnight. The reaction mixture was filtrated and the solvent was removed under vacuum. The residue was purified with column chromatography on silica using n-heptane-EtOAc (4 :1) to yield 0.216 g (5%) of the title compound. MS (m/e): 322.0 (M+H⁺).

10 (4-Fluoro-phenyl)-(4-methyl-piperidin-4-yl)-methanone; compound with trifluoro-acetic acid

The title compound was synthesized from (4-Fluoro-phenyl)-(4-methyl-piperidin-4-yl)-methanone (0.215g, 0.6 mmol) and trifluoroacetic acid (1.4mL, 6 mmol) in 5 mL of dichloromethane to yield 0.328 g of a yellow solid that was used on the next step without purification. MS (m/e): 222.3 (M+H⁺).

15 Step 2

(4-Fluoro-phenyl)-(4-methyl-piperidin-4-yl)-methanone

Intermediate E

Trans (4-{2-[4-(4-Fluoro-benzoyl)-4-methyl-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester

20 According to the procedure described for the synthesis of Trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester (intermediate E, example 1), the title compound was synthesized from (4-Fluoro-phenyl)-(4-methyl-piperidin-4-yl)-methanone and Trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester. MS (m/e): 447.4 (M+H⁺).

25 Intermediate F

{1-trans-[2-(4-Amino-cyclohexyl)-ethyl]-4-methyl-piperidin-4-yl}-(4-fluoro-phenyl)-methanone

According to the procedure described for the synthesis of {1-trans-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone, trifluoroacetic acid salt (intermediate F, example 1), the title compound was synthesized from Trans (4-{2-[4-(4-

30

Fluoro-benzoyl)-4-methyl-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester and trifluoroacetic acid. MS (m/e): 347.4 (M+H⁺).

Trans N-(4-{2-[4-(4-Fluoro-benzoyl)-4-methyl-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

- 5 According to the procedure described for the synthesis of example 36 the title compound was synthesized from the {1-trans-[2-(4-Amino-cyclohexyl)-ethyl]-4-methyl-piperidin-4-yl}-(4-fluoro-phenyl)-methanone and the corresponding acetyl chloride. MS (m/e): 389.4 (M+H⁺).

Example 58

- 10 N-Trans-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide

Intermediate E

Trans-(4-{2-[4-(2,4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester

- 15 According to the procedure described for the synthesis of Trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester (intermediate E, example 1), the title compound was synthesized from 4-(2,4-fluorobenzoyl) piperidine and Trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester. MS (m/e): 451.5 (M+H⁺).

- 20 Intermediate F

{1-trans-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone; compound with trifluoro-acetic acid

- According to the procedure described for the synthesis of {1-trans-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone, trifluoroacetic acid salt
25 (intermediate F, example 1), the title compound was synthesized from Trans-(4-{2-[4-(2,4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester and trifluoroacetic acid. MS (m/e): 351.5 (M+H⁺).

N-trans-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide

According to the procedure described for the synthesis of {4-Chloro-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide (example 1) the title compound was synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone (*example 58, intermediate F*) and 3-methoxy-propionic acid using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate and N- ethyldiisopropylamine in DMF. MS (m/e): 437.0 (M+H⁺).

According to the procedure described for the synthesis of example 58 further derivatives have been synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone (*example 58, intermediate F*) and the corresponding acid.

10 The purification was performed with preparative HPLC on reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective amides which comprise examples 58 to example 63A18 .

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) +
58	N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide	436.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and 3-methoxy-propionic acid	437.0
59	N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-ethoxy-benzamide	498.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and 4-ethoxy-benzoic	499.2

			acid	
60	N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide	536.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and 3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzoic acid	537.3
61	Tetrahydro-furan-3-carboxylic acid trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	448.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and Tetrahydro-furan-3-carboxylic acid	449.0
62	N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	392.4	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and acetic acid	393.4
63	Tetrahydro-pyran-4-carboxylic acid trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	462.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and	463.4

			Tetrahydro-pyran-4-carboxylic acid	
63A1	N trans -(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide	406.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and propionic acid	407.3
63A2	4-Chloro-N-(4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	406.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and propionic acid and 4-Chloro benzoic acid	407.3
63A3	Cyclopropanecarboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	418.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and propionic acid and Cyclopropanecarboxylic acid	419.4
63A4	Cyclobutanecarboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	432.5	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and	433.3

			propionic acid and Cyclobutanecarbo- xylic acid	
63A5	5-Methanesulfonyl- thiophene-2- carboxylic acid (4-{2- [4-(2,4-difluoro- benzoyl)-piperidin-1- yl]-ethyl}-cyclohexyl)- amide	538.6	Trans-{1-[2-(4- Amino- cyclohexyl)-ethyl]- piperidin-4-yl]- (2,4-difluoro- phenyl)- methanone and propionic acid and 5- Methanesulfonyl- thiophene-2- carboxylic acid	538.5
63A6 63A7 63A8	Chroman-3- carboxylic acid (4-{2- [4-(2,4-difluoro- benzoyl)-piperidin-1- yl]-ethyl}-cyclohexyl)- amide	510.6	Trans-{1-[2-(4- Amino- cyclohexyl)-ethyl]- piperidin-4-yl]- (2,4-difluoro- phenyl)- methanone and propionic acid and Chroman-3- carboxylic acid (note : Chiral separation yields both enantiomers)	511.5
63A9	Biphenyl-4-carboxylic acid (4-{2-[4-(2,4- difluoro-benzoyl)- piperidin-1-yl]-ethyl}- cyclohexyl)-amide	530.7	{1-[2-(4-amino- cyclohexyl)-ethyl]- piperidin-4-yl]- (2,4-difluoro- phenyl)- methanone and biphenyl-4- carboxylic acid	530.9
63A10	N-trans (4-{2-[4-(2,4- Difluoro-benzoyl)- piperidin-1-yl]-ethyl}-	540.6	Trans {1-[2-(4- amino- cyclohexyl)-ethyl]-	541.0

	cyclohexyl)-6-morpholin-4-yl-nicotinamide		piperidin-4-yl)-(2,4-difluorophenyl)-methanone 2-morpholino nicotinic acid	
63A11	N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide	473.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2,4-difluorophenyl)-methanone and 3-methyl 5-isoxazoleacetic acid	474.6
63A12	4-Trifluoromethyl-cyclohexanecarboxylic acid trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	528.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2,4-difluorophenyl)-methanone and 4-Trifluoromethyl-cyclohexanecarboxylic acid	529.2
63A13	N-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide	539.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2,4-difluorophenyl)-methanone and 4-morpholino benzoic acid	540.3
63A14	N-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-	408.4	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-	409.4

	hydroxy-acetamide		(2,4-difluoro-phenyl)-methanone and 2-hydroxy-acetic acid	
63A15	(R)-N-Trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-propionamide	436.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and 2-methoxy-propionamide	437.4
63A16	2-Benzoyloxy-N-trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	498.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and 2-Benzoyloxy acetic acid	499.3
63A17	(S)-Tetrahydro-furan-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	448.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and (S)-Tetrahydro-furan-3-carboxylic acid	449.4
63A18	(R)-Tetrahydro-furan-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-	448.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-	449.3

	cyclohexyl)-amide		methanone and (R)-Tetrahydro- furan-3-carboxylic acid	
--	-------------------	--	--	--

Example 64Trans-1-(4-Chloro-phenyl)-3-(4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea

- 5 The title compound was synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone (*example 58, intermediate F*) and 4-Chloro phenyl isocyanate in acetonitrile according to the procedure described for example 38. MS (m/e): 504.3 (M+H⁺).

- According to the procedure described for the synthesis of example 64, further urea
 10 derivatives were synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone (*example 58, intermediate F*) and the respective commercially available isocyanate. The purification was performed with preparative HPLC on reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective ureas which
 15 comprise examples 64 and example 65.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
64	1-(4-Chloro-phenyl)-3-trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea	504.02	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and 4-Chloro phenyl	504.3

			isocyanate	
65	1-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl] trans - ethyl}-cyclohexyl)-3-(4-ethoxy-phenyl)-urea	513.6	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and 4-ethoxy phenyl isocyanate	514.5

According to the procedure described for the synthesis of example 42A1 further derivatives have been synthesized from the respective trans-{1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone (*example 58, intermediate F*) and the corresponding amine. They comprise examples 65A1 to 65A4.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H)+
65A1	4-Phenyl-piperazine-1-carboxylic acid trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	538.7	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone hydrochloride and 1-phenylpiperazine	539.0
65A2	2,3-Dihydro-indole-1-carboxylic acid (4-{2-[4-(2,4-difluoro-	495.6	{1-[2-(4-amino-cyclohexyl)-ethyl]-	496.2

	benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-amide		piperidin-4-yl)-(2,4-difluoro-phenyl)-methanone hydrochloride and indoline	
65A4	Morpholine-4-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-amide	463.6	{1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2,4-difluoro-phenyl)-methanone hydrochloride and morpholine	464.2
65A4	Pyrrolidine-1-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-amide	447.6	{1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2,4-difluoro-phenyl)-methanone hydrochloride and pyrrolidine	448.3

Example 65A5Quinoline-4-carboxylic acid trans (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-amide

- 5 The title compound was prepared according to example 1 from Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2,4-difluoro-phenyl)-methanone and Quinoline-4-carboxylic acid to yield a white solid. (m/e): 506.3 (M+H⁺).

Further amide derivates were synthesized from Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2,4-difluoro-phenyl)-methanone and the respective acid. The purification
 10 was performed with preparative HPLC on reversed phase column material eluting with a

gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective amides which comprise examples 65A5 to example 65A17 .

Ex. No	Systematic name	MW	Starting materials	MW found (M+H)+
65A5	Quinoline-4-carboxylic acid trans (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	505.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and Quinoline-4-carboxylic acid	506.3
65A6	Tetrahydro-furan-3-carboxylic acid trans (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	448.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone Tetrahydro-furan-3-carboxylic acid	449.4
65A7	Cyclopropanecarboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	418.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and Cyclopropanecarboxylic acid	419.3

65A8	5-Methanesulfonyl-thiophene-2-carboxylic acid (4-{2-[4-(3,4-difluorobenzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	538.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluorophenyl)-methanone and 5-Methanesulfonyl-thiophene-2-carboxylic acid	539.5
65A9	N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-butyramide	420.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluorophenyl)-methanone and butyric acid	421.1
65A10	2,2-Difluoro-cyclopropanecarboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	454.3	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluorophenyl)-methanone and 2,2-Difluoro-cyclopropanecarboxylic acid	455.3
65A11	Tetrahydro-pyran-4-carboxylic acid (4-{2-[4-(3,4-difluorobenzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	462.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluorophenyl)-	463.4

			methanone and Tetrahydro-pyran-4-carboxylic acid	
65A12	2-Cyclopropyl-N-(4-{2-[4-(3,4-difluorobenzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	432.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluorophenyl)-methanone and 2-Cyclopropyl acetamide	433.2
65A13	Chroman-3-carboxylic acid (4-{2-[4-(3,4-difluorobenzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	510.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluorophenyl)-methanone and Chroman-3-carboxylic acid	511.5
65A14	4-Cyano-N-trans (4-{2-[4-(3,4-difluorobenzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	479.5	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluorophenyl)-methanone and 4-cyano benzoic acid	480.5
65A15	N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyrrol-	519.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-	520.2

	1-yl-benzamide		(2,4-difluoro-phenyl)-methanone and 4-pyrrol benzoic acid	
65A16	N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyrrol-1-yl-benzamide	519.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and 4-pyrrol benzoic acid	520.2
65A17	N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide	539.6	Trans {1-[2-(4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-difluoro-phenyl)-methanone and 4-morpholine benzoic acid	540.5

Example 65A18

2-Benzyloxy-N-trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

Step15 1-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethanone

2-Chloro-4- fluoro-1-iodobenzol (5 g, 19 mmol) is solved in THF (3mL) and at -10°C isopropyl magnesium chloride-lithium chloride (2M in THF) was added dropwise and the mixture stirred for 30 minutes at °0 C. At -10°C 1-acetyl-isonipecotoyl chloride is added (3.3 g, 18 mmol) solved in THF (2mL) and the mixture stirred for 10 minutes to -10°C and
 10 4 h to °0C. Water was added and the reaction extracted with dichloromethane.

Chromatography with Heptane/ EtOAc (2:1) gave the desired compound as a clear orange liquid (1.8 g, 33% yield). (m/e): 284.3 (M+H⁺).

Step 2

(2-Chloro-4-fluoro-phenyl)-piperidin-4-yl-methanone; hydrochloride

- 5 1-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethanone (1.8 g, 6.5 mmol) was solved in 6 N HCl (17mL) and water was added 17 mL . The mixture is stirred at reflux overnight. Diethylether (20 mL) was added and the reaction extracted . The organic phase was discarded and to the water an aqueous solution (10%) of sodium hydroxide was added until pH 11 and was extracted with dichloromethane. Removal of the solvent gave 1.1g, 5
10 mmol of the title compound (66% yield). (m/e): 242.3 (M+H⁺).

Intermediate E and F

Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone

- The title compound was prepared following the steps already described on example 1 from
15 (2-Chloro-4-fluoro-phenyl)-piperidin-4-yl-methanone and Trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester following removal of the Boc protecting group by treatment with trifluoroacetic acid. (m/e): 367.4 (M+H⁺).

- 2-Benzyloxy-N-trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide
20

The title compound was prepared as described on example 1 from Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate, N-ethyldiisopropylamine and 2-Benzyloxy acetic acid in DMF. (m/e): 515.3 (M+H⁺).

- 25 According to the procedure described for the synthesis of example 65A18 further derivatives have been synthesized from Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone and the corresponding acid. The purification was performed with preparative HPLC on reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of

the product fractions yielded the respective amides which comprise examples 65A18 to example 65A28.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H)+
65A18	2-Benzyloxy-N-trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	515.1	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone and 2-Benzyloxy acetic acid	515.3
65A19	N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide	556.1	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone and 4-morpholine benzoic acid	556.1
65A20	Tetrahydro-furan-3-carboxylic acid trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	465.1	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone and Tetrahydro-furan-3-carboxylic acid	465.3
65A21	Cyclopropanecarboxylic acid trans (4-{2-[4-(2-chloro-4-fluoro-	434.9	Trans {1-[2-(4-Amino-cyclohexyl)-	435.4

	benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-amide		ethyl]-piperidin-4-yl)-(2-chloro-4-fluoro-phenyl)-methanone and Cyclopropanecarboxylic acid	
65A22	N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-butyramide	437.0	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2-chloro-4-fluoro-phenyl)-methanone and butyric acid	437.4
65A23	N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-2-cyclopropyl-acetamide	449.0	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2-chloro-4-fluoro-phenyl)-methanone and 2-cyclopropyl-acetic acid	449.4
65A24	N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-propionamide	437.0	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2-chloro-4-fluoro-phenyl)-methanone and propionic acid	437.4
65A25	Tetrahydro-pyran-4-carboxylic acid (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl)-cyclohexyl)-amide	479.04	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl)-(2-chloro-4-fluoro-phenyl)-methanone and Tetrahydro-	479.3

			pyran-4-carboxylic acid	
65A26	5-Methanesulfonyl-thiophene-2-carboxylic acid (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	555.1	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone and 5-Methanesulfonyl-thiophene-2-carboxylic acid	555.3
65A27	N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide	453.0	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone and 3-methoxy-propionic acid	453.2
65A28	4-Chloro-N-trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide	505.1	Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone and 4-Chloro benzoic acid	505.4

Example 65A29N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

- 5 Prepared as described on example 36 from Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone and acetyl chloride. MS (m/e): 409.4 (M+H⁺)

Example 664-Ethoxy-N {4-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-butyl}-benzamide10 Intermediate AC{4-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-butyl}-carbamic acid tert-butyl ester

- 4-(4-fluorobenzoyl) piperidine hydrochloride (0.5 g, 2.01 mmol) is suspended in acetonitrile (5mL), 4-(Boc-amino) Butyl Bromide was added (0.569 g, 2.01 mmol) and sodium iodide (0.461g, 3.02 mmol) and the mixture was stirred at 80°C overnight. Water
15 was added and the aqueous phase was extracted with 30 mL dichloromethane. The combined organic phases were dried with magnesium sulfate, filtrated concentrated and purified with column chromatography on silica using dichloromethane/ Methanol (95/0.5) to yield 0.830 g, (2.1 mmol, 100% yield) of the title compound as a brown solid. MS (m/e): 379.2 (M+H⁺).

20 Intermediate AD[1-(4-Amino-butyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt

- According to the procedure described for the synthesis of Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone, trifluoroacetic acid salt
25 (intermediate F), the title compound was synthesized from {4-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-butyl}-carbamic acid tert-butyl ester and trifluoroacetic acid. MS (m/e): 279.2 (M+H⁺).

4-Ethoxy-N-{4-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-butyl}-benzamide

According to the procedure described for the synthesis of {4-Chloro-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide (example 1) the title compound was synthesized from Trans-[1-(4-Amino-butyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-Ethoxy benzoic acid using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate and N-ethyl-diisopropylamine in DMF. MS (m/e): 427.3 (M+H⁺).

Following the procedure described for the synthesis of example 66, further amide derivatives were synthesized from [1-(4-Amino-butyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and the respective commercially available acid. The purification was performed with preparative HPLC on reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective amides which comprise examples 66 and example 68.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
66	4-Ethoxy-N-{4-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-butyl}-benzamide	426.5	[1-(4-Amino-butyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-Ethoxy benzoic acid	427.3
67	N-{4-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-butyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide	464.5	[1-(4-Amino-butyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzoic acid	465.1
68	Tetrahydro-furan-3-carboxylic acid {4-[4-	376.4	[1-(4-Amino-butyl)-piperidin-4-	377.2

	(4-fluoro-benzoyl)-piperidin-1-yl]-butyl]-amide		yl)-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and Tetrahydro-furan-3-carboxylic acid	
--	---	--	--	--

Example 691-(4-Chloro-phenyl)-3-{4-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-butyl}-urea

The title compound was synthesized from Trans-[1-(4-Amino-butyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-Chloro phenyl isocyanate in
5 acetoneitrile according to the procedure described for example 38. MS (m/e): 432.05 (M⁺).

Following the procedure described for the synthesis of example 59, further ureas were synthesized using the respective commercially available isocyanate. The purification was performed with preparative HPLC on reversed phase column material eluting with a
10 gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective ureas.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
69	1-(4-Chloro-phenyl)-3-{4-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-butyl}-urea	431.9	[1-(4-Amino-butyl)-piperidin-4-yl]-(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-Chlorophenyl isocyanate	432.5
70	1-(4-Ethoxy-phenyl)-3-{4-[4-(4-fluoro-benzoyl)-piperidin-1-	491.5	[1-(4-Amino-butyl)-piperidin-4-yl]-	492.4

	yl]-butyl}-urea		(4-fluoro-phenyl)-methanone; trifluoro-acetic acid salt and 4-4-Ethoxyphenyl isocyanate	
--	-----------------	--	---	--

Example 71

Quinoline-4-carboxylic acid trans-(4-{2-[4-(2-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

5 Intermediate E

Trans-(4-{2-[4-(2-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester

According to the procedure described for the synthesis of Trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester (intermediate E, example 1), the title compound was synthesized from 4-{2-[4-(2-chloro-benzoyl)]
 10 piperidine and Trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester. MS (m/e): 450.1 (M+H⁺).

Intermediate F

Trans-[1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl]-(2-chloro-phenyl)-methanone;
 15 trifluoro-acetic acid salt

According to the procedure described for the synthesis of {1-trans-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-phenyl)-methanone, trifluoroacetic acid salt (intermediate F, example 1), the title compound was synthesized from Trans-(4-{2-[4-(2-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester and
 20 trifluoroacetic acid. MS (m/e): 349.5 (M+H⁺).

Quinoline-4-carboxylic acid trans-(4-{2-[4-(2-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

According to the procedure described for the synthesis of {4-Chloro-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide (example 1) the title compound was synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-phenyl)-methanone; trifluoro-acetic acid salt and Quinoline-4-carboxylic acid using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate and N- ethyldiisopropylamine in DMF. MS (m/e): 504.4 (M+H⁺).

Further amide derivates were synthesized from Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-phenyl)-methanone; trifluoro-acetic acid salt and the respective commercially available acid. The purification was performed with preparative HPLC on reversed phase column material eluting with a gradient formed from acetonitrile /water (0.05% Et₃N). The evaporation of the product fractions yielded the respective amides which comprise examples 71 to example 72.

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
71	Quinoline-4-carboxylic acid trans-(4-{2-[4-(2-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	504.07	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-phenyl)-methanone; trifluoro-acetic acid salt and Quinoline-4-carboxylic acid	504.4
72	N-trans (4-{2-[4-(2-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide	390.9	Trans-{1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-phenyl)-methanone;	391.3

			trifluoro-acetic acid salt and Acetic Acid	
--	--	--	--	--

Example 73N-trans (4-{2-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide5 Step 11-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethanone

1-acetylisonipecotoyl chloride (8g, 42 mmol) was solved in dichlorobenzene and aluminium chloride (11.2 gr, 894 mmol) was added portionwise. The mixture was refluxed at 90°C for 4 h after complexation of the reaction. Ice/ water was added to the mixture that
10 was extracted with dichloromethane. After chromatography from heptane to EtOAc the product was obtained as a yellow oil (6.3 g, 50%). MS (m/e): 300.2 (M+H⁺)

Step 2(2,4-Dichloro-phenyl)-piperidin-4-yl-methanone

Removal of the acetyl protecting group was performed refluxing on 6 N HCl as described
15 on example 65A18 . MS (m/e): 258.0 (M+H⁺)

Intermediate ETrans (4-{2-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester

The title compound was prepared as described on example 1 from (2,4-Dichloro-phenyl)-
20 piperidin-4-yl-methanone and Trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester (m/e): 483.4 (M+H⁺)

Intermediate FTrans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-dichloro-phenyl)-methanone

25 The title compound was prepared as described on example 1 from Trans (4-{2-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester and trifluoroacetic acid (m/e): 383.3 (M+H⁺).

N- trans (4-{2-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide

The title compound was prepared as described on example 1 from Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,4-dichloro-phenyl)-methanone and 4-morpholino benzoic acid using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium tetrafluoroborate and N- ethyldiisopropylamine in DMF (m/e): 572.3 (M+H⁺)

Example 74

N-Trans (4-{2-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

Prepared as described on example 36 from Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2, 4-Dichloro-phenyl)-methanone and acetyl chloride. MS (m/e): 425.3 (M+H⁺)

Example 75

N-Trans (4-{2-[4-(2,5-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

1-[4-(2,5-Dichloro-benzoyl)-piperidin-1-yl]-ethanone

The title compound was prepared according as described on example 65A18 from 2, 5 Dichloro 1-iodobenzol, isopropyl magnesium chloride-lithium chloride (2M in THF) and 1-acetyl-isonipecotoyl chloride. (m/e): 301.1 (M+H⁺).

(2,5-Dichloro-phenyl)-piperidin-4-yl-methanone

Removal of the acetyl protecting group was performed refluxing on 6 N HCl as described on example 65A18 . MS (m/e): 258.1 (M+H⁺)

Intermediate E

Trans (4-{2-[4-(2,5-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester

The title compound was prepared as described on example 1 from (2,5-Dichloro-phenyl)-piperidin-4-yl-methanone and Trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester (m/e): 483.5 (M+H⁺)

Intermediate F

Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2,5-dichloro-phenyl)-methanone

The title compound was prepared as described on example 1 from Trans (4-{2-[4-(2,5-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester and
5 trifluoroacetic acid (m/e): 383.0 (M+H⁺).

N-Trans (4-{2-[4-(2,5-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

Prepared as described on example 36 from Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2, 4-Dichloro-phenyl)-methanone and acetyl chloride. MS (m/e): 425.3 (M+H⁺).

10 Example 76

N-Trans (4-{2-[4-(4-Fluoro-2-methyl-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

Prepared as described on example 36 from Trans {1-[2-(4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-fluoro-2-methyl-phenyl)-methanone (prepared as the Trans {1-[2-(4-
15 Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(2-chloro-4-fluoro-phenyl)-methanone described on example 65A18 and acetyl chloride. MS (m/e): 389.1 (M+H⁺).

General procedure A.1 for the reductive amination

A mixture of amine hydrochloride (1.0 eq.) and aldehyde (1.1 eq.) in 1,2-dichloroethane
20 (ca. 0.2 M) was stirred over night at room temperature. Na(AcO)₃BH (1.5 eq.) was added and the reaction was monitored by TLC and MS. After completion sat. aq. NHCO₃ sol. was added and the product was extracted with CH₂Cl₂. After drying (Na₂SO₄ or MgSO₄) the solvent was evaporated and the product purified by flash chromatography.

25 General procedure A.2 for the reductive amination

A mixture of amine hydrochloride (1.0 eq.) aldehyde (1.1 eq.) and AcOH (2.0 eq.) in 1,2-dichloroethane (ca. 0.2 M) was stirred over night at room temperature. Na(AcO)₃BH (1.5 eq.) was added and the reaction was monitored by TLC and MS. After completion sat. aq.

NHCO₃ sol. was added and the product was extracted with CH₂Cl₂. After drying (Na₂SO₄ or MgSO₄) the solvent was evaporated and the product purified by flash chromatography.

General procedure B.1 for the Boc cleavage

- 5 A mixture of Boc protected amine (1.0 eq.), MeOH (10 eq.) and 4.6 M HCl in EtOAc (15 eq.) was stirred until no more starting material was detected by TLC and MS. The solid product was collected by filtration and dried under HV.

General procedure B.2 for the Boc cleavage

- 10 To a solution of Boc protected amine (1.0 eq.) in CH₂Cl₂ (ca. 0.2 M) was added a saturated solution of HCl in Et₂O (1/2 the volume of CH₂Cl₂). The mixture was stirred until no more starting material was detected by TLC and MS. The product was precipitated by addition of Et₂O, collected by filtration, washed with more Et₂O and dried under HV.

15 General procedure C for the amide formation

- To a stirred solution under N₂ of acid (1.1 eq.) in DMF (ca. 0.1 M) was added TBTU (1.1 eq.) and Et₃N (3.1 eq.). After stirring 1 h at room temperature the amine hydrochloride was added (1.0 eq.). Stirring was continued and the reaction was monitored by TLC and MS. After completion sat. aq. NHCO₃ sol. was added and the product was extracted with 3
20 portions of EtOAc. After drying (Na₂SO₄ or MgSO₄) the solvent was evaporated and the crude product was purified by flash chromatography.

General procedure D

- A 1.6 M solution of *n*-BuLi (1.1 eq.) in Hex was added dropwise to a solution under inert
25 atmosphere of the thiophene (1.1 eq.) in THF (0.1 M) at -78 °C. After stirring 2 h at -78 °C 4-formyl-piperidine-1-carboxylic acid tert-butyl ester (1.0 eq.) dissolved in a small amount of THF was added. Stirring at -78 °C was continued 2.5 h then the reaction mixture was allowed to warm to room temperature, poured into EtOAc and washed with sat. aq. NaHCO₃ sol. The aqueous layers were extracted with more EtOAc. The combined

organic layers were dried (Na_2SO_4 or MgSO_4), the solvent was evaporated and the product purified by flash chromatography.

General procedure E.1 for the MnO_2 oxidation of alcohols to ketones

- 5 MnO_2 (20 eq.) was added to a solution of alcohol (1.0 eq.) in CH_2Cl_2 (0.1 M). The resulting mixture was stirred over night at 30 °C. Filtration over Dicalite and evaporation of the solvent afforded the crude product that was purified by flash chromatography.

General procedure E.2 for the TPAP oxidation of alcohols to ketones

- 10 The alcohol (1.0 eq.) was dissolved in CH_2Cl_2 (0.25 M), powdered 4Å molecular sieves (500 mg/mmol) and NMO were added followed by tetrapropylammonium perruthenate (0.05 eq.). The reaction mixture was stirred at room temperature and monitored by TLC. After completion the mixture was diluted with CH_2Cl_2 then washed with 1 M aq. Na_2SO_3 solution, brine and finally a 1 M aq. CuSO_4 solution. Drying (Na_2SO_4 or MgSO_4) and
15 evaporation of the solvent afforded the crude product that was purified by flash chromatography.

Example 77

N-{*trans*-4-[2-(4-Benzoyl-piperidin-1-yl)-ethyl]-cyclohexyl}-acetamide

Step 1

- 20 {*trans*-4-[2-(4-Benzoyl-piperidin-1-yl)-ethyl]-cyclohexyl}-carbamic acid *tert*-butyl ester

From 4-benzoylpiperidine hydrochloride (200 mg) and [*trans*-4-(2-oxo-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (intermediate C, 235 mg) by procedure A.2. Yield: 181 mg (49%). Off-white solid. MS (m/z): 415.3 ($[\text{M}+\text{H}]^+$).

- 25 Step 2

{1-[2-(*trans*-4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-phenyl-methanone dihydrochloride

From {*trans*-4-[2-(4-benzoyl-piperidin-1-yl)-ethyl]-cyclohexyl}-carbamic acid *tert*-butyl ester (172 mg) by procedure B.1. Yield: 148 mg (92%). White solid. MS (*m/z*): 315.1 ([M+H]⁺).

5 Step 3

N-{*trans*-4-[2-(4-Benzoyl-piperidin-1-yl)-ethyl]-cyclohexyl}-acetamide

From {1-[2-(*trans*-4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-phenyl-methanone dihydrochloride (138 mg) and acetic acid (23 mg) by procedure C. Yield: 85 mg (66%). White solid. 357.3 ([M+H]⁺).

10

Example 78

N-(*trans*-4-{2-[4-(4-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide

Step 1

15 (*trans*-4-{2-[4-(4-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid *tert*-butyl ester

From (4-chlorophenyl)(4-piperidyl)methanone hydrochloride (100 mg) and [*trans*-4-(2-oxo-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (intermediate C, 102 mg) by procedure A.1. Yield: 128 mg (74%). Light yellow solid. MS (*m/z*): 449.3 ([M+H]⁺).

20

Step 2

{1-[2-(*trans*-4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-chloro-phenyl)-methanone dihydrochloride

From (4-{2-[4-(4-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid *tert*-butyl ester by procedure B.2. Yield: 100 mg (84%). White solid. MS (*m/z*): 349.3 ([M+H]⁺).

25

Step 3

N-(trans-4-{2-[4-(4-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide

From {1-[2-(trans-4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-chloro-phenyl)-methanone dihydrochloride (100 mg) and 4-morpholin-4-yl-benzoic acid. Yield: 56 mg
 5 (40%). MS (*m/z*): 538.5([M+H]⁺).

Examples 79 and 80

Examples 79 and 80 were prepared in analogy to example 78:

Ex. No	Systematic name	MW	Starting materials	MW found (M+H) ⁺
79	Tetrahydro-pyran-4-carboxylic acid (trans-4-{2-[4-(4-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	461.05	From {1-[2-(trans-4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-chloro-phenyl)-methanone dihydrochloride and tetrahydro-pyran-4-carboxylic acid	461.5
80	(R,S)-Chroman-3-carboxylic acid (trans-4-{2-[4-(4-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide	509.09	From {1-[2-(trans-4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(4-chloro-phenyl)-methanone dihydrochloride and (R,S)-3-chromanecarboxylic acid	509.3

Intermediate AG*N*-[*trans*-4-(2-Oxo-ethyl)-cyclohexyl]-acetamideAE (*trans*-4-Acetylamino-cyclohexyl)-acetic acid ethyl ester

- (*trans*-4-Amino-cyclohexyl)-acetic acid ethyl ester hydrochloride (10.0 g, 45 mmol, intermediate B) was dissolved in CH₂Cl₂ (150 ml) and Et₃N and AcCl (3.89 g, 50 mmol) were added. The reaction mixture was stirred 3 h at room temperature before washing it with H₂O and brine. After drying (Na₂SO₄) the solvent was evaporated to yield 8.42 g (82 %, 37 mmol) of a white solid. MS (*m/z*): 228.3 ([M+H]⁺).

10

AF *N*-[*trans*-4-(2-Hydroxy-ethyl)-cyclohexyl]-acetamide

- LiAlH₄ (2.10 g, 55 mmol) and THF (150 ml) were placed in a dry balloon. After cooling this mixture to 0 °C a solution of (*trans*-4-acetylamino-cyclohexyl)-acetic acid ethyl ester (8.42 g, 37 mmol) in little THF was added dropwise. The reaction was stirred 1 h before careful neutralization with H₂O (5.6 ml), 1 N NaOH (3 x 5.6 ml) and more H₂O (5.6 ml). The resulting mixture was stirred over night before filtering off the solids. Evaporation of the solvent and drying under high vacuum afforded 5.25 g (76%, 28 mmol) of a light brown solid. MS (*m/z*): 186.4 ([M+H]⁺).

- 20 AG *N*-[*trans*-4-(2-Oxo-ethyl)-cyclohexyl]-acetamide

- DMSO (3.68 g, 47 mmol) in CH₂Cl₂ (20 ml) was added at -78 °C to a stirred solution of oxalylchloride (2.9 g, 23 mmol) in CH₂Cl₂ (100 ml). After 1 h stirring at -78 °C a solution of *N*-[*trans*-4-(2-hydroxy-ethyl)-cyclohexyl]-acetamide (2.18 g, 12 mmol) in CH₂Cl₂ (80 ml) was added followed after 2 h by Et₃N (7.14 g, 71 mmol). The mixture was allowed to reach room temperature and was then diluted with H₂O and extracted with CH₂Cl₂. The combined organic layers were dried (Na₂SO₄) and the solvent was evaporated to afford the crude product. Chromatography (CH₂Cl₂/MeOH 95:5) yielded 1.75 g (81 %, 9.5 mmol) of a light brown solid. MS (*m/z*): 184.3 ([M+H]⁺).

25

Example 81N-(trans-4-{2-[4-(Thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamideStep 14-(Hydroxy-thiophen-2-yl-methyl)-piperidine-1-carboxylic acid tert-butyl ester

- 5 From thiophene (130 mg) and 4-formyl-piperidine-1-carboxylic acid tert-butyl ester (300 mg) by procedure D. Yield: 167 mg (40%). Yellow oil. MS (m/z): 298.1 ($[M+H]^+$).

Step 24-(Thiophene-2-carbonyl)-piperidine-1-carboxylic acid tert-butyl ester

- 10 From 4-(hydroxy-thiophen-2-yl-methyl)-piperidine-1-carboxylic acid tert-butyl ester (127 mg) by procedure E.1. Yield: 117 mg (93%). Yellow oil. MS (m/z): 296.2 ($[M+H]^+$).

Step 3Piperidin-4-yl-thiophen-2-yl-methanone hydrochloride

- 15 From 4-(thiophene-2-carbonyl)-piperidine-1-carboxylic acid tert-butyl ester (115 mg) by procedure B.2. Yield: 74 mg (82%). Yellow solid. MS (m/z): 196.0 ($[M+H]^+$).

Step 4N-(trans-4-{2-[4-(Thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

- 20 From piperidin-4-yl-thiophen-2-yl-methanone hydrochloride (74 mg) and N-[trans-4-(2-oxo-ethyl)-cyclohexyl]-acetamide (64 mg, intermediate AG). Yield: 75 mg (65%). Light yellow solid. MS (m/z): 363.4 ($[M+H]^+$).

Example 82

(R,S)-Chroman-3-carboxylic acid (*trans*-4-{2-[4-(3-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

Step 1

4-[(3-Chloro-thiophen-2-yl)-hydroxy-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

- 5 From 3-chlorothiophene (612 mg) and 4-formyl-piperidine-1-carboxylic acid *tert*-butyl ester (1.00 g) by procedure D. Yield: 420 mg (27%). Yellow solid. MS (*m/z*): 332.2 ([M+H]⁺).

Step 2

- 10 4-(3-Chloro-thiophene-2-carbonyl)-piperidine-1-carboxylic acid *tert*-butyl ester

From 4-[(3-chloro-thiophen-2-yl)-hydroxy-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (420 mg) by procedure E.2. Yield: 255 mg (61%). Light yellow oil. MS (*m/z*): 330.2 ([M+H]⁺).

- 15 Step 3

(3-Chloro-thiophen-2-yl)-piperidin-4-yl-methanone hydrochloride

From 4-(3-chloro-thiophene-2-carbonyl)-piperidine-1-carboxylic acid *tert*-butyl ester (255 mg) by procedure B.2. Yield: 178 mg (86%). White solid. MS (*m/z*): 230.4 ([M+H]⁺).

- 20 Step 4

(*trans*-4-{2-[4-(3-Chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid *tert*-butyl ester

- 25 From (3-chloro-thiophen-2-yl)-piperidin-4-yl-methanone hydrochloride (100 mg) and [*trans*-4-(2-oxo-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (intermediate C, 91 mg) by procedure A.1. Yield: 85 mg (50%). White foam. MS (*m/z*): 455.3 ([M+H]⁺).

Step 5

{1-[2-(*trans*-4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(3-chloro-thiophen-2-yl)-methanone dihydrochloride

- From (*trans*-4-{2-[4-(3-Chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester (85 mg) by procedure B.2. Yield: 60 mg (75%). White solid. MS (*m/z*): 355.3 ([M+H]⁺).

Step 6

- 10 (R,S)-Chroman-3-carboxylic acid (*trans*-4-{2-[4-(3-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

From {1-[2-(*trans*-4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(3-chloro-thiophen-2-yl)-methanone dihydrochloride (30 mg) and (R,S)-chromanecarboxylic acid by procedure C. Yield: 1 mg (2.7%). White solid. MS (*m/z*): 515.3 ([M+H]⁺).

- 15 Example 83

N-(*trans*-4-{2-[4-(3-Chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

- From (3-chloro-thiophen-2-yl)-piperidin-4-yl-methanone hydrochloride (78 mg) and *N*-[*trans*-4-(2-oxo-ethyl)-cyclohexyl]-acetamide (54 mg, intermediate AG) by procedure A.1. 20 Yield: 52 mg (45%). White solid. MS (*m/z*): 397.1 ([M+H]⁺).

Example 84

N-(*trans*-4-{2-[4-(5-Chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

- 25 Step 1

4-[5-Chloro-thiophen-2-yl]-hydroxy-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester

From 2-chlorothiophene (183 mg) and 4-formyl-piperidine-1-carboxylic acid *tert*-butyl ester (300 mg) by procedure D. Yield: 180 mg (38%). Brown oil. MS (*m/z*): 332.1 ([M+H]⁺).

5 Step 2

4-(5-Chloro-thiophene-2-carbonyl)-piperidine-1-carboxylic acid *tert*-butyl ester

From 4-[(5-chloro-thiophen-2-yl)-hydroxy-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (20 mg) by procedure E.1. Yield: 18 mg (90%). Yellow oil. MS (*m/z*): 330.2 ([M+H]⁺).

10

Step 3

(5-Chloro-thiophen-2-yl)-piperidin-4-yl-methanone hydrochloride

From 4-(5-chloro-thiophene-2-carbonyl)-piperidine-1-carboxylic acid *tert*-butyl ester (12 mg) by procedure B.2. Yield: 10 mg (100%). White solid. MS (*m/z*): 230.3 ([M+H]⁺).

15

Step 4

N-(*trans*-4-[2-[4-(5-Chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl]-cyclohexyl)-acetamide

From (5-chloro-thiophen-2-yl)-piperidin-4-yl-methanone hydrochloride (10 mg) and *N*-[*trans*-4-(2-oxo-ethyl)-cyclohexyl]-acetamide (7 mg, intermediate AG) by procedure A.1. Yield: 9 mg (59%). White solid. MS (*m/z*): 397.4 ([M+H]⁺).

20

Example 85

Benzo[1,3]dioxole-5-carboxylic acid (*trans*-4-[2-[4-(5-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl]-cyclohexyl)-amide

25

Step 1

(trans-4-{2-[4-(5-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid tert-butyl ester

- From (5-chloro-thiophen-2-yl)-piperidin-4-yl-methanone hydrochloride (585 mg) and [trans-4-(2-oxo-ethyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (intermediate C, 530 mg) by procedure A.2. Yield: 513 mg (51%). Light yellow solid. MS (*m/z*): 455.2 ([M+H]⁺).

Step 2

{1-[2-(trans-4-Amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(5-chloro-thiophen-2-yl)-methanone dihydrochloride

- 10 From (trans-4-{2-[4-(5-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid *tert*-butyl ester (1.14 g) by procedure B.1. Yield: 970 mg (91%). Light grey solid. MS (*m/z*): 355.1 ([M+H]⁺).

Step3

- 15 Benzo[1,3]dioxole-5-carboxylic acid (trans-4-{2-[4-(5-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide

From {1-[2-(trans-4-amino-cyclohexyl)-ethyl]-piperidin-4-yl}-(5-chloro-thiophen-2-yl)-methanone dihydrochloride (100 mg) and benzo[1,3]dioxole-5-carboxylic acid (45 mg) by procedure C. Yield: 62 mg (52%). Off-white solid. MS (*m/z*): 503.2 ([M+H]⁺).

20

Example 86

N-(trans-4-{2-[4-(5-Fluoro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

Step 1

- 25 4-[(5-Fluoro-thiophen-2-yl)-hydroxy-methyl]-piperidine-1-carboxylic acid tert-butyl ester

A 1.6 M solution of *n*-BuLi in Hex (3.71 ml, 5.9 mmol) was added to a cooled (-78 °C) solution of thiophene (500 mg, 5.9 mmol) in THF (15 ml) under Ar. After stirring 30 min

at -78 °C a solution of *N*-fluorodibenzenesulfonimide (1.87 g, 5.9 mmol) in THF (10 ml) was added. Stirring at -78 °C was continued for 10 min before slow rising of the temperature to 0 °C over a period of 15 min. A solid precipitate was formed. The mixture was cooled to -78 °C, a 1.6 M *n*-BuLi solution in Hex (3.71 ml, 0.59 ml) was added, then it
5 was stirred 10 min before addition of 4-formyl-piperidine-1-carboxylic acid *tert*-butyl ester (836 mg, 3.9 mmol) in THF (5 ml). After stirring 30 min at -78 °C the solution was slowly warmed to room temperature. Sat. aq. NH₄Cl sol. (5 ml) was added, the mixture was diluted with EtOAc (100 ml) and washed with sat. aq. NH₄Cl sol. (100 ml), sat. aq. NaHCO₃ (2 x 100 ml) and brine (100 ml). After drying (Na₂SO₄) and evaporation of the
10 solvent, the crude product was purified by chromatography (amino modified silica gel, Hept to EtOAc) to yield 971 mg (79%) of a brown oil. MS (*m/z*): 316.1 ([M+H]⁺).

Step 2

4-(5-Fluoro-thiophene-2-carbonyl)-piperidine-1-carboxylic acid *tert*-butyl ester

15 From 4-[(5-fluoro-thiophen-2-yl)-hydroxy-methyl]-piperidine-1-carboxylic acid *tert*-butyl ester (968 mg) by procedure E.2. MeCN (0.6 ml) was added to the reaction mixture. Yield: 577 mg (60%). Light brown gum. MS (*m/z*): 336.4 ([M+Na]⁺).

Step 3

20 (5-Fluoro-thiophen-2-yl)-piperidin-4-yl-methanone hydrochloride

From 4-(5-fluoro-thiophene-2-carbonyl)-piperidine-1-carboxylic acid *tert*-butyl ester (51 mg) by procedure B.1. Yield: 20 mg (49%). Off-white solid. MS (*m/z*): 214.1 ([M+H]⁺).

Step 4

25 *N*-(*trans*-4-{2-[4-(5-Fluoro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide

From (5-fluoro-thiophen-2-yl)-piperidin-4-yl-methanone hydrochloride (17 mg) and *N*-[*trans*-4-(2-oxo-ethyl)-cyclohexyl]-acetamide (20 mg, intermediate AG) by procedure A.2. Yield: 19 mg (73%). White solid. MS (*m/z*): 381.3 ($[M+H]^+$).

5

Example A

Film coated tablets containing the following ingredients can be manufactured in a conventional manner:

<u>Ingredients</u>	<u>Per tablet</u>	
Kernel:		
Compound of formula (I)	10.0 mg	200.0 mg
Microcrystalline cellulose	23.5 mg	43.5 mg
Lactose hydrous	60.0 mg	70.0 mg
Povidone K30	12.5 mg	15.0 mg
Sodium starch glycolate	12.5 mg	17.0 mg
Magnesium stearate	1.5 mg	4.5 mg
(Kernel Weight)	120.0 mg	350.0 mg
Film Coat:		
Hydroxypropyl methyl cellulose	3.5 mg	7.0 mg
Polyethylene glycol 6000	0.8 mg	1.6 mg
Talc	1.3 mg	2.6 mg
Iron oxide (yellow)	0.8 mg	1.6 mg
Titanium dioxide	0.8 mg	1.6 mg

The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magnesiumstearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution /
5 suspension of the above mentioned film coat.

Example B

Capsules containing the following ingredients can be manufactured in a conventional manner:

<u>Ingredients</u>	<u>Per capsule</u>
Compound of formula (I)	25.0 mg
Lactose	150.0 mg
Maize starch	20.0 mg
Talc	5.0 mg

10 The components are sieved and mixed and filled into capsules of size 2.

Example C

Injection solutions can have the following composition:

Compound of formula (I)	3.0 mg
Gelatine	150.0 mg
Phenol	4.7 mg
Sodium carbonate	to obtain a final pH of 7
Water for injection solutions	ad 1.0 ml

Example D

15 Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:

Capsule contents

Compound of formula (I)	5.0 mg
Yellow wax	8.0 mg
Hydrogenated Soya bean oil	8.0 mg
Partially hydrogenated plant oils	34.0 mg
Soya bean oil	110.0 mg
Weight of capsule contents	165.0 mg
Gelatin capsule	
Gelatin	75.0 mg
Glycerol 85 %	32.0 mg
Karion 83	8.0 mg (dry matter)
Titanium dioxide	0.4 mg
Iron oxide yellow	1.1 mg

The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.

5

Example E

Sachets containing the following ingredients can be manufactured in a conventional manner:

Compound of formula (I)	50.0 mg
Lactose, fine powder	1015.0 mg
Microcrystalline cellulose (AVICEL PH 102)	1400.0 mg


Sodium carboxymethyl cellulose	14.0 mg
Polyvinylpyrrolidone K 30	10.0 mg
Magnesium stearate	10.0 mg
Flavoring additives	1.0 mg

The active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the flavoring additives and filled into 5 sachets.

-141-

Claims

1. A compound of formula (I):



wherein:

A is aryl or 5 to 6 membered heteroaryl optionally substituted by one to five substituents selected from the group consisting of cyano, halo, C₁₋₆-alkyl, C₁₋₆-haloalkyl, C₁₋₆-alkylsulfonyl, or C₁₋₆-alkoxy;

n is 1, 2, 3 or 4;

p is 1, 2, 3 or 4;

q is 1;

r is 0, 1, 2 or 3;

R¹ is C₂₋₆-alkenyl or C₂₋₆-alkynyl substituted by aryl,

or is C₁₋₆-alkyl optionally substituted by one to five substituents selected from the group consisting of:

halo,

hydroxy,

C₁₋₆-alkyl,

C₁₋₆-haloalkyl,

-CO(O)-C₁₋₆-alkyl,

C₃₋₁₀-cycloalkyl,

C₁₋₆-alkoxy optionally substituted by one, two or three halo or substituted by aryl,

aryl optionally substituted by halo or C₁₋₆-alkoxy,

5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl, and

phenoxy,

or is C₁₋₆-alkoxy,

or is C₃₋₁₀-cycloalkyl optionally substituted by one or more R^a,

or is 4 to 10 membered heterocycloalkyl optionally substituted by one or more R^a,

or is aryl optionally substituted by one or more R^a,

or is 5 to 10 membered heteroaryl optionally substituted by one or more R^a,

HD/IG 03.07.2007

-142-

or is $-NR^bR^c$, wherein R^b is H or C_{1-6} -alkyl and wherein R^c is H, C_{1-6} -alkyl or aryl optionally substituted by one or more R^a ,

wherein R^a is selected from:

halo,

cyano,

oxo,

hydroxy,

halobenzenesulfonyl,

C_{1-6} -alkyl optionally substituted by one, two or three substituents selected from the group consisting of:

5 to 10 membered heterocycloalkyl, and

aryl which is optionally substituted by halo or by C_{1-6} -alkoxy,

C_{1-6} -haloalkyl,

C_{1-6} -haloalkoxy,

C_{1-6} -alkoxy optionally substituted by aryl or 5 to 10 membered heteroaryl which is optionally substituted by C_{1-6} -alkyl,

aryloxy,

$-NH(CO)-C_{1-6}$ -alkyl,

$-O(CO)-C_{1-6}$ -alkyl,

C_{1-6} -alkylsulfonyl,

aryl,

4 to 10 membered heterocycloalkyl optionally substituted by hydroxy, C_{1-6} -alkyl or oxo,

5 to 10 membered heteroaryl optionally substituted by C_{1-6} -alkyl or oxo, and

$di(C_{1-6})$ alkylamino;

R^2 is H, OH, C_{1-6} -alkyl or halo;

as well as pharmaceutically acceptable salts thereof.

2. The compound of formula (I) according to claim 1, wherein:

A is aryl or 5 to 6 membered heteroaryl optionally substituted by halo, C_{1-6} -alkyl or C_{1-6} -alkoxy;

n is 2, 3 or 4;

p is 1, 2 or 3;

HD/IG 03.07.2007

-143-

q is 1;

r is 0 or 1;

R^1 is C_{1-6} -alkyl optionally substituted by one or more halo, C_{1-6} -alkoxy or aryl optionally substituted by halo,
 or is C_{3-10} -cycloalkyl optionally substituted by one or more R^a ,
 or is 5 to 10 membered heterocycloalkyl optionally substituted by one or more R^a ,
 or is aryl optionally substituted by one or more R^a ,
 or is 5 to 10 membered heteroaryl optionally substituted by one or more R^a ,
 or is $-NR^bR^c$, wherein R^b is H or C_{1-6} -alkyl and wherein R^c is aryl optionally substituted by one or more R^a ,

wherein R^a is selected from:

halo,

cyano,

oxo,

halobenzenesulfonyl,

C_{1-6} -alkyl optionally substituted by aryl which is substituted by halo,

 C_{1-6} -haloalkyl, C_{1-6} -haloalkoxy,

C_{1-6} -alkoxy optionally substituted by 5 to 6 membered heteroaryl which is optionally substituted by C_{1-6} -alkyl,


 $-NH(CO)-C_{1-6}$ -alkyl,

5 to 6 membered heterocycloalkyl, and

5 to 6 membered heteroaryl optionally substituted by C_{1-6} -alkyl or oxo; R^2 is H, OH or halo;

as well as pharmaceutically acceptable salts thereof.

3. A compound of formula (Ia) according to claim 1:



wherein A, R^1 and R^2 are as defined in claim 1 or 2.

4. A compound of formula (Ia) according to claim 3, wherein:

HD/IG 03.07.2007

-144-

- A is aryl or 5 to 6 membered heteroaryl optionally substituted by one to five substituents selected from the group consisting of halo or C₁₋₆-alkoxy;
- R¹ is C₂₋₆-alkynyl substituted by aryl,
or is C₁₋₆-alkyl optionally substituted by one to five substituents selected from the group consisting of:
halo,
hydroxy,
-CO(O)-C₁₋₆-alkyl,
C₃₋₁₀-cycloalkyl,
C₁₋₆-alkoxy optionally substituted by aryl,
aryl optionally substituted by halo or C₁₋₆-alkoxy,
5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl, and
phenoxy,
or is C₁₋₆-alkoxy,
or is C₃₋₁₀-cycloalkyl optionally substituted by one or more R^a and R^a is selected from the group consisting of one, two, three C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, oxo, C₁₋₆-haloalkyl and halo,
or is 4 to 10 membered heterocycloalkyl optionally substituted by one or more R^a and R^a is selected from the group consisting of one, two, three phenyl, phenoxy and C₁₋₆-alkyl,
or is aryl optionally substituted by one or more R^a and R^a is selected from the group consisting of:
cyano,
C₁₋₆-alkyl optionally substituted by 5 to 6 membered heterocycloalkyl,
halo,
C₁₋₆-haloalkyl,
C₁₋₆-haloalkoxy,
C₁₋₆-alkoxy optionally substituted by 5 to 6 membered heteroaryl which is optionally substituted by C₁₋₆-alkyl,
5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl,
4 to 10 membered heterocycloalkyl optionally substituted by hydroxy, by oxo or by C₁₋₆-alkyl,
-NH(CO)-C₁₋₆-alkyl,
halobenzenesulfonyl,
phenyl and
di(C₁₋₆)alkylamino;

HD/IG 03.07.2007

-145-

or is 5 to 10 membered heteroaryl optionally substituted by one or more R^a and R^a is selected from the group consisting of:

halo,

C_{1-6} -alkyl optionally substituted by aryl which is substituted by halo,

C_{1-6} -alkoxy,

Oxo,

C_{1-6} -haloalkoxy,

C_{1-6} -alkylsulfonyl,

5 to 6 membered heterocycloalkyl optionally substituted by C_{1-6} -alkyl, and aryl,

or is $-NR^bR^c$, wherein R^b is H or C_{1-6} -alkyl and wherein R^c is H, C_{1-6} -alkyl or aryl optionally substituted by one or more R^a , and R^a is selected from the group consisting of: halo, C_{1-6} -alkyl and C_{1-6} -alkoxy;

R^2 is H, OH, C_{1-6} -alkyl or halo;

as well as pharmaceutically acceptable salts thereof.

5. The compound of formula (Ia) according to claim 4, wherein R^1 is 5 to 10 membered heteroaryl optionally substituted by one or more R^a .

6. The compound of formula (Ia) according to claim 5, wherein it is selected from the group consisting of:

2-Methyl-2H-indazole-3-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

6-Chloro-2-methyl-quinoline-3-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Chloro-1-(3,4-dichloro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-methyl-nicotinamide;

[1,8]Naphthyridine-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Fluoro-1H-indole-2-carboxylic acid (trans-4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Trifluoromethoxy-1H-indole-2-carboxylic acid (trans-4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

HD/IG 03.07.2007

-146-

5-Methoxy-1H-indole-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Thiophene-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

3H-Imidazo[4,5-b]pyridine-6-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Methanesulfonyl-thiophene-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

6-Fluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-nicotinamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-morpholin-4-yl-nicotinamide;

3-Methyl-chroman-3-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

2-Morpholin-4-yl-pyrimidine-5-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

6-Morpholin-4-yl-pyridazine-3-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Morpholin-4-yl-pyrazine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Benzo[1,3]dioxole-5-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

3-Methyl-isoxazole-5-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Trans N-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-isonicotinamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-morpholin-4-yl-nicotinamide;

2,3-Dihydro-benzo[1,4]dioxine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-(4-Methyl-piperazin-1-yl)-pyridine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Morpholin-4-yl-pyridine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

HD/IG 03.07.2007

-147-

5-Phenyl-pyridine-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Quinoline-4-carboxylic acid trans- (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Quinoline-4-carboxylic acid trans-(4-{2-[4-(4-methoxy-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Quinoline-4-carboxylic acid trans-{4-[2-(4-benzoyl-4-hydroxy-piperidin-1-yl)-ethyl]-cyclohexyl}-amide;

Quinoline-4-carboxylic acid trans-{4-[2-(4-benzoyl-4-fluoro-piperidin-1-yl)-ethyl]-cyclohexyl}-amide;

Quinoline-4-carboxylic acid trans-(4-{2-[4-(3,4-dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

2,3-Dihydro-indole-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

6-Trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

1,3-Dihydro-isoindole-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

3,4-Dihydro-1H-isoquinoline-2-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Quinoline-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-4-hydroxy-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Methanesulfonyl-thiophene-2-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Chroman-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

(R)-Chroman-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

(S)-Chroman-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-6-morpholin-4-yl-nicotinamide;

2,3-Dihydro-indole-1-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

HD/IG 03.07.2007

-148-

Quinoline-4-carboxylic acid *trans* (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Methanesulfonyl-thiophene-2-carboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Chroman-3-carboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

5-Methanesulfonyl-thiophene-2-carboxylic acid (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Quinoline-4-carboxylic acid (4-{2-[4-(2-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Chroman-3-carboxylic acid (*trans*-4-{2-[4-(4-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Chroman-3-carboxylic acid (*trans*-4-{2-[4-(3-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide; and

Benzo[1,3]dioxole-5-carboxylic acid (*trans*-4-{2-[4-(5-chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide.

7. The compound of formula (Ia) according to claim 4, wherein R^1 is $-NR^bR^c$, wherein R^b is H or C_{1-6} -alkyl and wherein R^c is H, C_{1-6} -alkyl or aryl optionally substituted by one or more R^a .

8. The compound of formula (Ia) according to claim 7, wherein it is selected from the group consisting of:

Trans 1-(2,4-Dichloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea;

Trans 1-(4-Chloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea;

Trans 1-(4-Ethoxy-phenyl)-3-(4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea;

Trans 1-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-p-tolyl-urea;

Trans 1-(4-Chloro-phenyl)-3-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-1-methyl-urea;

Trans 3-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-1,1-dimethyl-urea;

HD/IG 03.07.2007

-149-

Trans 1-(4-Chloro-phenyl)-3-(4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea;

Trans 1-(4-Chloro-phenyl)-3-(4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-urea; and

Trans 1-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(4-ethoxy-phenyl)-urea.

9. The compound of formula (Ia) according to claim 4, wherein R¹ is aryl optionally substituted by one or more R^a.

10. The compound of formula (Ia) according to claim 9, wherein it is selected from the group consisting of:

4-Chloro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

4-(3,5-Dimethyl-isoxazol-4-ylmethoxy)-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-trifluoromethyl-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyrrol-1-yl-benzamide;

4-Ethoxy-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

4-Acetylamino-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl)-benzamide;

4-Cyano-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyrazol-1-yl-benzamide;

HD/IG 03.07.2007

-150-

2,4-Dichloro-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

4-(4-Chloro-benzenesulfonyl)-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-trifluoromethoxy-benzamide;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(1,1,2,2-tetrafluoro-ethoxy)-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyridin-3-yl-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyridin-4-yl-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyridin-2-yl-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-phthalazin-1-yl-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-4-pyridin-2-yl-benzamide;

Biphenyl-4-carboxylic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

2-Fluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

4-(3,3-Dimethyl-2-oxo-azetidin-1-yl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-ylmethyl-benzamide;

4-tert-Butoxy-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

4-Dimethylamino-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

4-(1,1-Dioxo-6-thiomorpholin-4-yl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

HD/IG 03.07.2007

-151-

3-Fluoro-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(3-hydroxy-pyrrolidin-1-yl)-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-(4-hydroxy-piperidin-1-yl)-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-thiomorpholin-4-yl-benzamide; N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-piperidin-1-yl-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-morpholin-4-yl-benzamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-4-hydroxy-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;

N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-ethoxy-benzamide;

N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;

4-Chloro-N-(4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

Biphenyl-4-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

N-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

4-Cyano-N-trans (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-pyrrol-1-yl-benzamide;

N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide;

4-Chloro-N-trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide;

N-trans (4-{2-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide; and

HD/IG 03.07.2007

-152-

N-(*trans*-4-{2-[4-(4-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-4-morpholin-4-yl-benzamide.

11. The compound of formula (Ia) according to claim 4, wherein R¹ is C₃₋₁₀-cycloalkyl optionally substituted by one or more R^a.

12. The compound of formula (Ia) according to claim 11, wherein it is selected from the group consisting of:

Cyclopropanecarboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Cyclohexanecarboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Adamantane-1-carboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

2-Cyclopropyl-*N*-*trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

2-Methyl-cyclopropanecarboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

4-Methoxy-cyclohexanecarboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

4-Hydroxy-cyclohexanecarboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

(1*S*,4*R*)-Bicyclo[2.2.1]heptane-2-carboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

(1*R*,4*R*)-7,7-Dimethyl-2-oxo-bicyclo[2.2.1]heptane-1-carboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

4-Trifluoromethyl-cyclohexanecarboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

1-Methyl-cyclohexanecarboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

4-Methyl-cyclohexanecarboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

6-Hydroxy-bicyclo[2.2.2]octane-2-carboxylic acid *trans* (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

HD/IG 03.07.2007

-153-

1-Trifluoromethyl-cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

3-Chloro-cyclobutanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

1-Hydroxy-cyclopropanecarboxylic acid (trans-4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Cyclobutanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

4-Hydroxy-cyclohexanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

2,2-Difluoro-cyclopropanecarboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Cyclopropanecarboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Cyclobutanecarboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

4-Trifluoromethyl-cyclohexanecarboxylic acid trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Cyclopropanecarboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

2,2-Difluoro-cyclopropanecarboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide; and

Cyclopropanecarboxylic acid trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide.

13. The compound of formula (Ia) according to claim 4, wherein R^1 is 5 to 10 membered heterocycloalkyl optionally substituted by one or more R^a .

14. The compound of formula (Ia) according to claim 13, wherein it is selected from the group consisting of:

Tetrahydro-pyran-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-furan-3-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

HD/IG 03.07.2007

-154-

Morpholine-4-carboxylic acid trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

3-Phenoxy-pyrrolidine-1-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

1,1-Dioxo-thiomorpholine-4-carboxylic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-furan-3-carboxylic acid trans-(4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-furan-3-carboxylic acid trans-(4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

(S)-Tetrahydro-furan-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

(R)-Tetrahydro-furan-3-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

4-Phenyl-piperazine-1-carboxylic acid trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Morpholine-4-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Pyrrolidine-1-carboxylic acid (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-furan-3-carboxylic acid trans (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-pyran-4-carboxylic acid (4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-furan-3-carboxylic acid trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide;

Tetrahydro-pyran-4-carboxylic acid (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide; and

Tetrahydro-pyran-4-carboxylic acid (*trans*-4-{2-[4-(4-chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide.

15. The compound of formula (Ia) according to claim 4, wherein R¹ is C₁₋₆-alkyl optionally substituted by one to five substituents selected from the group consisting of:

halo,

hydroxy,

HD/IG 03.07.2007

-155-

C₁₋₆-alkyl,
-CO(O)-C₁₋₆-alkyl,
C₃₋₁₀-cycloalkyl,
C₁₋₆-alkoxy optionally substituted by one, two or three halo or substituted by aryl,
aryl optionally substituted by halo or C₁₋₆-alkoxy,
5 to 10 membered heteroaryl optionally substituted by C₁₋₆-alkyl, and
phenoxy.

16. The compound of formula (Ia) according to claim 15, wherein it is selected from the group consisting of:

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;

2-(4-Chloro-phenyl)-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-isobutyramide;

3-Ethoxy-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide;

3,3,3-Trifluoro-N-trans-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide;

2,2,2-Trifluoro-N-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-butyramide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-butyramide;

N-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-phenoxy-propionamide;

N-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-hydroxy-2,2-dimethyl-propionamide;

2-Benzo[d]isoxazol-3-yl-N-(4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide;

2-(3,5-Dimethoxy-phenyl)-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

HD/IG 03.07.2007

-156-

2-Benzo[1,3]dioxol-5-yl-N-trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

Acetic acid trans (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexylcarbamoyl)-methyl ester;

N-trans-(4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-Fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-Fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;

Trans N-(4-{2-[4-(4-Fluoro-benzoyl)-4-methyl-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;

N trans -(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide;

N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide;

N-(4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-hydroxy-acetamide;

(R)-N-Trans (4-{2-[4-(2,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-propionamide;

2-Benzyloxy-N-trans (4-{2-[4-(2,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-butyramide;

2-Cyclopropyl-N-(4-{2-[4-(3,4-difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(3,4-Difluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide;

2-Benzyloxy-N-trans (4-{2-[4-(2-chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-butyramide;

N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-2-cyclopropyl-acetamide;

HD/IG 03.07.2007

-157-

N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-propionamide;

N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;

N-trans (4-{2-[4-(2-Chloro-4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-trans (4-{2-[4-(2-Chloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-Trans (4-{2-[4-(2,4-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-Trans (4-{2-[4-(2,5-Dichloro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-Trans (4-{2-[4-(4-Fluoro-2-methyl-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-{trans-4-[2-(4-Benzoyl-piperidin-1-yl)-ethyl]-cyclohexyl}-acetamide;

N-(trans-4-{2-[4-(3-Chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-(trans-4-{2-[4-(5-Chloro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide;

N-(trans-4-{2-[4-(5-Fluoro-thiophene-2-carbonyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-acetamide.

17. The compound of formula (Ia) according to claim 4, wherein R¹ is C₁₋₆-alkoxy.

18. The compound of formula (Ia) according to claim 17, wherein it is selected from the group consisting of:

Trans (4-{2-[4-(4-Fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-carbamic acid methyl ester; and

4-Ethoxy-N-trans (4-{2-[4-fluoro-4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-benzamide.


19. The compound of formula (Ia) according to claim 4, wherein R¹ is C₂₋₆-alkynyl or C₂₋₆-alkynyl substituted by aryl.

20. The compound of formula (Ia) according to claim 19, wherein it is 3-Phenyl-propynoic acid (4-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-cyclohexyl)-amide.

21. A compound of formula (Ib) according to claim 1:

HD/IG 03.07.2007

-158-



wherein A, R¹ and R² are as defined in claim 1 or 2 for formula (I).


22. The compound of formula (Ib) according to claim 21, wherein it is selected from the group consisting of:

2-(4-Chloro-phenyl)-N-[(1S,2S)-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl]-isobutyramide;

N-{Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide; and

1-(4-Chloro-phenyl)-3-{trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclobutylmethyl}-urea.

23. A compound of formula (Ic) according to claim 1:



wherein A, R¹ and R² are as defined in claim 1 or 2 for formula (I).

24. The compound of formula (Ic) according to claim 23, wherein it is selected from the group consisting of:

N-{Trans-2-[4-(4-Fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-3-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzamide;

1-(4-Chloro-phenyl)-3-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-urea;

2-(4-Chloro-phenyl)-N-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-isobutyramide; and

4-Chloro-N-{Trans-2-[4-(4-fluoro-benzoyl)-piperidin-1-ylmethyl]-cyclopropylmethyl}-benzamide.

HD/IG 03.07.2007

-159-

25. A medicament containing one or more compounds as claimed in any one of claims 1 to 24 and pharmaceutically acceptable excipients for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

26. A compound in accordance with any one of claims 1 to 24 as well as its pharmaceutically acceptable salt for use in the treatment or prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

27. The use of a compound in accordance with any one of claims 1 to 24 as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

HD/IG 03.07.2007